{
  "model_name": "meta-llama/Llama-3.1-8B-Instruct",
  "article_id": "longhealth_group_00_patients_01-05",
  "question_ids": [
    "patient_01_q0",
    "patient_01_q1",
    "patient_01_q2",
    "patient_01_q3",
    "patient_01_q4",
    "patient_01_q5",
    "patient_01_q6",
    "patient_01_q7",
    "patient_01_q8",
    "patient_01_q9",
    "patient_01_q10",
    "patient_01_q11",
    "patient_01_q12",
    "patient_01_q13",
    "patient_01_q14",
    "patient_01_q15",
    "patient_01_q16",
    "patient_01_q17",
    "patient_01_q18",
    "patient_01_q19",
    "patient_02_q0",
    "patient_02_q1",
    "patient_02_q2",
    "patient_02_q3",
    "patient_02_q4",
    "patient_02_q5",
    "patient_02_q6",
    "patient_02_q7",
    "patient_02_q8",
    "patient_02_q9",
    "patient_02_q10",
    "patient_02_q11",
    "patient_02_q12",
    "patient_02_q13",
    "patient_02_q14",
    "patient_02_q15",
    "patient_02_q16",
    "patient_02_q17",
    "patient_02_q18",
    "patient_02_q19",
    "patient_03_q0",
    "patient_03_q1",
    "patient_03_q2",
    "patient_03_q3",
    "patient_03_q4",
    "patient_03_q5",
    "patient_03_q6",
    "patient_03_q7",
    "patient_03_q8",
    "patient_03_q9",
    "patient_03_q10",
    "patient_03_q11",
    "patient_03_q12",
    "patient_03_q13",
    "patient_03_q14",
    "patient_03_q15",
    "patient_03_q16",
    "patient_03_q17",
    "patient_03_q18",
    "patient_03_q19",
    "patient_04_q0",
    "patient_04_q1",
    "patient_04_q2",
    "patient_04_q3",
    "patient_04_q4",
    "patient_04_q5",
    "patient_04_q6",
    "patient_04_q7",
    "patient_04_q8",
    "patient_04_q9",
    "patient_04_q10",
    "patient_04_q11",
    "patient_04_q12",
    "patient_04_q13",
    "patient_04_q14",
    "patient_04_q15",
    "patient_04_q16",
    "patient_04_q17",
    "patient_04_q18",
    "patient_04_q19",
    "patient_05_q0",
    "patient_05_q1",
    "patient_05_q2",
    "patient_05_q3",
    "patient_05_q4",
    "patient_05_q5",
    "patient_05_q6",
    "patient_05_q7",
    "patient_05_q8",
    "patient_05_q9",
    "patient_05_q10",
    "patient_05_q11",
    "patient_05_q12",
    "patient_05_q13",
    "patient_05_q14",
    "patient_05_q15",
    "patient_05_q16",
    "patient_05_q17",
    "patient_05_q18",
    "patient_05_q19"
  ],
  "question_ids_hash": "8ff2a53ae8fb0c0b",
  "max_new_tokens": 2048,
  "generations": [
    {
      "question_id": "patient_01_q0",
      "generated_text": "The current treatment regimen for Mrs. Sample's DLBCL is R-Pola-CHP, which consists of Polatuzumab vedotin, Rituximab, Cyclophosphamide, and Doxorubicin.\n\nStep 1: Identify the treatment regimen: R-Pola-CHP\nStep 2: List the drugs in the regimen: Polatuzumab vedotin, Rituximab, Cyclophosphamide, Doxorubicin\nStep 3: Check the options against the treatment regimen:\n- A. Polatuzumab vedotin: Part of the regimen\n- B. Rituximab: Part of the regimen\n- C. Cyclophosphamide: Part of the regimen\n- D. Vincristine: Not part of the regimen\n- E. Doxorubicin: Part of the regimen\n\nThe correct answer is D."
    },
    {
      "question_id": "patient_01_q1",
      "generated_text": "To answer this question, let's review the provided information about Mrs. Sample's diagnoses.\n\nShe has a diagnosis of DLBCL (Diffuse Large B-cell Lymphoma) and multiple sclerosis (MS), which is described as a primary progressive type. She also has a mood disorder and 2-vessel coronary heart disease (CHD). Additionally, she has amyotrophic lateral sclerosis (ALS), which is mentioned in the context of her neurological examination.\n\nConsidering these diagnoses, the statement that does NOT accurately reflect Mrs. Sample's condition is:\n\nD. She has 3-vessel CHD.\n\nThis is because the provided information only mentions 2-vessel CHD, not 3-vessel CHD.\n\n**D**"
    },
    {
      "question_id": "patient_01_q2",
      "generated_text": "To answer this question, let's analyze the given information about Mrs. Sample:\n\n1. The patient, Anna Sample, is being treated for Diffuse Large B-Cell Lymphoma (DLBCL).\n2. The patient has a history of chronic inflammatory CNS disease, specifically mentioned as Multiple Sclerosis (MS) in the text_0 section.\n3. There is no mention of dementia, Parkinson's disease, brain abscess, or autoimmune encephalitis in the provided text.\n\nBased on the information, the correct answer is:\n\nA. Multiple sclerosis"
    },
    {
      "question_id": "patient_01_q3",
      "generated_text": "To answer this question, I need to find the information about the medication Fingolimod in the text and determine the correct dosage and administration time for Mrs. Sample.\n\nStep 1: Find the relevant text snippet about Fingolimod in the patient's information.\n\nStep 2: Identify the dosage and administration time of Fingolimod mentioned in the text.\n\nThe text snippet is: \"Fingolimod - 0.5mg, 1 capsule at bedtime, Note: Take a break as directed\"\n\nStep 3: Match the identified information with the given options.\n\nThe correct answer is B."
    },
    {
      "question_id": "patient_01_q4",
      "generated_text": "Let's analyze the information step by step:\n\n1. The patient, Mrs. Sample, is diagnosed with DLBCL (Diffuse Large B-Cell Lymphoma).\n2. The oncology board is considering various treatment options.\n3. The options provided are different chemotherapy regimens, each with a unique combination of drugs.\n\nGiven the information provided, we can see that the patient's treatment plan is mentioned in the text as \"Initiated R-Pola-CHP regimen q21\". This indicates that the patient is receiving a chemotherapy regimen that includes Rituximab (R), Polatuzumab (Pola), Cyclophosphamide (C), and Hydroxydaunorubicin (H) with Prednisone (P).\n\nBased on this information, the correct answer is:\n\n**D. 6 cycles of R-Pola-CHP**"
    },
    {
      "question_id": "patient_01_q5",
      "generated_text": "To determine where the metastasis was located, let's look at the provided text and follow the steps:\n\n1. The text mentions that Mrs. Sample had a surgical intervention on 12/21/2016 for a mass in the thoracic spine.\n2. The location of the mass is described as starting from the left pedicle of T10 with a significant extramedullary tumor mass and full spinal canal narrowing at the level of T10.\n3. Therefore, the metastasis was located in the thoracic vertebra 10.\n\n**C**"
    },
    {
      "question_id": "patient_01_q6",
      "generated_text": "To determine the correct answer, let's analyze the given information.\n\nThe text mentions that on 01/09/2017, Mrs. Sample received a CT scan of her whole body during the venous phase of contrast enhancement. The contrast agent used was given as \"Omnipaque 320\" in the text.\n\nSo, the correct answer is: **A**"
    },
    {
      "question_id": "patient_01_q7",
      "generated_text": "Let's analyze the radiologic examinations mentioned in the text for patient Anna Sample:\n\n1. MR Head 3D unenhanced + contrast from 12/19/2016\n2. MR Spine plain + post-contrast from 12/20/2016\n3. CT Thoracic Spine from 01/03/2017\n4. CT Thoracic Spine from 01/04/2017\n5. CT Chest/Abdomen/Pelvis + Contrast from 01/09/2017\n6. Extended Respiratory Function (Diffusion) from 01/15/2017\n7. Ultrasound of the abdomen was conducted (no specific date mentioned)\n8. MR Spine plain + post-contrast from 10/06/2017\n9. PET-CT from 10/09/2017\n10. Liver MRI from 10/11/2017\n\nBased on the information provided, the order of the radiologic examinations is: MR Head, MR Spine, CT Thoracic Spine, CT Whole Body is not mentioned, CT Thoracic Spine, CT Chest/Abdomen/Pelvis, Ultrasound, MR Spine, PET-CT, and Liver MRI.\n\nThe correct answer is not explicitly listed, but based on the information given, I will make a guess:\n\nA"
    },
    {
      "question_id": "patient_01_q8",
      "generated_text": "To determine the correct statement, let's analyze the medications listed in the patient's admission and discharge notes.\n\nAdmission medications:\n\n* Aspirin 100mg: Take 1 tablet in the morning\n* Atorvastatin 40mg: Take 1 tablet at bedtime\n* Sertraline 50mg: Take 2 tablets in the morning\n* Lorazepam 1mg: Take as needed\n* Fingolimod 0.5mg: Take 1 capsule at bedtime, Note: Take a break as directed\n* Hydromorphone hydrochloride 2mg (extended-release): Take 2 capsules in the morning and 2 capsules at bedtime\n* Melatonin 2mg (sustained-release): Take 1 tablet at bedtime\n* Baclofen (Lioresal) 10mg: Take 1 tablet three times a day\n* Pregabalin - Not listed\n* Prednisolone - Not listed\n* Melatonin 2mg - Listed as 2mg sustained-release, not 2mg as a new medication\n\nDischarge medications:\n\n* Aspirin 100mg: Take 1 tablet in the morning\n* Atorvastatin 40mg: Take 1 tablet at bedtime\n* Sertraline 50mg: Take 2 tablets in the morning\n* Lorazepam 1mg: Take as needed\n* Fingolimod 0.5mg: Take 1 capsule at bedtime, Note: Take a break as directed\n* Hydromorphone hydrochloride 2mg (extended-release): Take 2 capsules in the morning and 2 capsules at bedtime\n* Melatonin - Not listed\n* Baclofen (Lioresal) 10mg: Take 1 tablet three times a day\n* Pregabalin 75mg: Take 1 capsule in the morning and 1 capsule at bedtime\n* Prednisolone 50mg: Take 2 tablets in the morning, Continue through 02/19/2017\n* Melatonin - 2mg sustained-release was listed as a medication, but a new medication was not listed\n\nBased on the provided information, we can see that Pregabalin was not listed in the admission medications, but it was listed in the discharge medications. This suggests that the patient started taking Pregabalin between admission and discharge.\n\nThe other options do not match the changes in the patient's medications. Aspirin was not discontinued, Sertraline's dose was not increased, and there is no indication that the patient started taking 2mg of Melatonin in the evening or prednisolone was recommended to be continued for the rest of her life.\n\n**B**"
    },
    {
      "question_id": "patient_01_q9",
      "generated_text": "To determine the correct answer, let's analyze the medication changes from admission to discharge for Mrs. Sample.\n\n1. Admission medications:\n   - Aspirin (Aspirin\u00ae) 100mg\n   - Atorvastatin (Lipitor\u00ae) 40mg\n   - Sertraline (Zoloft\u00ae) 50mg\n   - Hydromorphone hydrochloride (Dilaudid\u00ae or Exalgo\u00ae) 2mg\n   - Lorazepam (Ativan\u00ae) 1mg\n   - Fingolimod (Gilenya\u00ae) 0.5mg\n   - Melatonin (sustained-release) 2mg\n   - Baclofen (Lioresal\u00ae) 10mg\n   - Pregabalin (Lyrica) 75mg\n   - MoviCOL (Macrogol, Sodium chloride, Potassium chloride) 1 packet three times a day\n   - Pantoprazole (Protonix) 40mg\n   - Colecalciferol (Vitamin D3) 20000 I.U.\n   - Co-trimoxazole - 960mg\n   - Valaciclovir - 500mg\n   - Prednisolone - 50mg\n   - Enoxaparin sodium (Clexane\u00ae) - 40mg (4000 I.U.)\n   - Dimenhydrinate (Vomex A) - 150mg (sustained-release), as needed for nausea, up to 2 capsules daily.\n\n2. Discharge medications:\n   - Aspirin (Aspirin) 100mg\n   - Atorvastatin (Lipitor) 40mg\n   - Sertraline (Zoloft) 50mg\n   - Hydromorphone hydrochloride (Dilaudid or Exalgo) 2mg (extended-release), 2 capsules in the morning and 2 capsules at bedtime\n   - Lorazepam (Ativan) 1mg, as needed\n   - Fingolimod (Gilenya) 0.5mg, 1 capsule at bedtime (take a break as directed)\n   - Melatonin (sustained-release) 2mg, 1 tablet at bedtime\n   - Baclofen (Lioresal) 10mg, 1 tablet three times a day\n   - Pregabalin (Lyrica) 75mg, 1 capsule in the morning and 1 capsule at bedtime\n   - MoviCOL (Macrogol, Sodium chloride, Potassium chloride) 1 packet three times a day, mixed with water for oral intake\n   - Pantoprazole (Protonix) 40mg, 1 tablet in the morning\n   - Colecalciferol (Vitamin D3) 20000 I.U., 1 capsule on Monday and Thursday\n   - Co-trimoxazole - 960mg, 1 tablet on Monday, Wednesday, and Friday\n   - Valaciclovir - 500mg, 1 tablet in the morning and 1 tablet at bedtime\n   - Prednisolone - 50mg, 2 tablets in the morning, Continue through 02/19/2017\n   - Enoxaparin sodium (Clexane) - 40mg (4000 I.U.), 1 injection at bedtime, Note: Continue in case of immobility\n   - Dimenhydrinate (Vomex A) - 150mg (sustained-release), as needed for nausea, up to 2 capsules daily.\n\nComparing the two lists, we can see that the frequency of Hydromorphone hydrochloride (Dilaudid or Exalgo) intake has not changed, as it remains 2 capsules in the morning and 2 capsules at bedtime. However, the medication changes do not indicate a decrease in cardiovascular risk, the introduction of a new gastrointestinal issue, the stabilization of the mood disorder, or the resolution of immobility concerns.\n\nGiven this analysis, the best answer is B, as the patient's pain management was escalated, as indicated by the continued use of Hydromorphone hydrochloride (Dilaudid or Exalgo) at the same frequency.\n\n**B**"
    },
    {
      "question_id": "patient_01_q10",
      "generated_text": "To answer this question, let's break down the information provided in the text and analyze it step by step.\n\n1. The patient, Mrs. Sample, has a diagnosis of DLBCL (Diffuse Large B-cell Lymphoma).\n2. She also has a diagnosis of multiple sclerosis (MS).\n3. The text mentions that the primary neurologist was unavailable for comments, but a consultation with an ambulatory physician is mentioned.\n4. The text states that it was decided to discontinue fingolimod (a medication for MS) and continue with Rituximab (a therapy for DLBCL) after a discussion with the oncology team.\n\nConsidering these points, let's analyze the options:\n\nA. This option mentions that an ambulatory physician recommended replacing Fingolimod with Rituximab on 02/24/2017, but it doesn't specify the reason for this recommendation.\n\nB. This option mentions that a consultation with an ambulatory physician recommended temporarily discontinuing the current medication for MS because the therapy for DLBCL is also an effective treatment. This option seems to align with the information provided in the text.\n\nC. This option mentions that the treatment was paused after a brain MRI showed no signs of active disease, but it doesn't mention anything about discontinuing the current medication for MS.\n\nD. This option mentions that the primary neurologist recommended discontinuing the current treatment and starting an alternative medication with Fingolimod, which contradicts the information provided in the text.\n\nE. This option mentions that the current therapy regime was discontinued because of possible adverse interactions with chemotherapy, but there is no mention of this in the text.\n\nBased on the analysis, the correct option is:\n\nB"
    },
    {
      "question_id": "patient_01_q11",
      "generated_text": "To determine which body part could not be assessed in the imaging examinations of Mrs. Sample, we need to analyze the provided text and identify the imaging examinations mentioned. The text mentions the following imaging examinations:\n\n* MRI of the brain\n* MRI of the spine\n* CT thoracic spine\n* CT thoracic spine from 01/03/2017\n* CT thoracic spine from 01/04/2017\n* CT thoracic spine from 01/09/2017\n* PET-CT from 01/15/2017\n* PET-CT from 10/09/2017\n* PET-CT from 10/11/2017\n\nThese imaging examinations primarily focused on the brain, spine, and thoracic region. They do not specifically mention any imaging of the liver, lungs, thyroid, or uterus.\n\nHowever, we can infer that the liver and lungs are likely to be assessed in the PET-CT examinations, as PET-CT is a whole-body imaging modality. The thyroid and uterus are not mentioned in the provided text, but they are not explicitly excluded either. However, considering the focus of the imaging examinations on the brain, spine, and thoracic region, it is less likely that they would include the uterus.\n\nGiven the options, the most likely answer is the feet, as they are not mentioned in the provided text and are not typically included in the standard imaging protocols for DLBCL.\n\n**E**"
    },
    {
      "question_id": "patient_01_q12",
      "generated_text": "Let's break down the information provided for Mrs. Sample.\n\nThe patient, Anna Sample, has a diagnosis of DLBCL (Diffuse large B-cell lymphoma). We need to determine which of the examinations listed were never performed.\n\nA. Bone marrow aspiration: This is mentioned in the text, specifically in the section \"Bone marrow aspiration: no infiltration from the pre-existing lymphoma.\"\n\nB. CSF aspiration: This is also mentioned in the text, specifically in the section \"CSF: no evidence of malignancy.\"\n\nC. MRI of the head: There is no mention of an MRI of the head in the provided text. However, there are mentions of MRI scans of the thoracolumbar spine, which might be related to the patient's symptoms and treatment.\n\nD. Pulmonary function testing: There is a mention of an \"Extended Respiratory Function (Diffusion) from 01/15/2017\" in the text, which suggests that some form of pulmonary function testing was performed.\n\nE. Cardiac stress testing: There is no mention of cardiac stress testing in the provided text.\n\nBased on the information provided, the examination that was never performed is:\n\nE"
    },
    {
      "question_id": "patient_01_q13",
      "generated_text": "To answer this question, let's break down the information provided in the patient's file.\n\nThe patient, Anna Sample, has been diagnosed with DLBCL (Diffuse large B-cell lymphoma). The immunohistochemical findings are mentioned in the file, specifically in the section \"Microscopy\" under the heading \"Molecular pathology report\".\n\nAccording to the report, the blastic tumor cells showed a positive reaction after incubation with antibodies against CD20, PAX5, and BCL2. Additionally, the Ki-67 proliferation index for these blastic tumor cells is > 90%.\n\nNow, let's match this information to the options:\n\nA. The blastic tumor cells showed a positive reaction after incubation with antibodies against CD20, CD30, and BCL2. The Ki-67 proliferation index for these blastic tumor cells is > 80%. \nB. The blastic tumor cells showed a positive reaction after incubation with antibodies against CD20, PAX5, and BCL2. The Ki-67 proliferation index for these blastic tumor cells is > 90%.\nC. The blastic tumor cells showed a positive reaction after incubation with antibodies against CD20, PAX5, and BCL2. The Ki-67 proliferation index for these blastic tumor cells is < 90%.\nD. The blastic tumor cells showed a positive reaction after incubation with antibodies against CD20, PAX5, BCL2, and CD10. The Ki-67 proliferation index for these blastic tumor cells is 50%.\nE. The blastic tumor cells showed a positive reaction only after incubation with antibodies against CD20 and PAX5. The Ki-67 proliferation index for these blastic tumor cells is > 90%.\n\nBased on the information provided, the correct answer is:\n\n**B**"
    },
    {
      "question_id": "patient_01_q14",
      "generated_text": "To answer this question, I will follow the steps below:\n\n1. Find the section of the text that describes the microscopy findings for the epidural tumor in Mrs. Sample.\n2. Look for the information about the percentage of positivity for Bcl-6.\n\nThe relevant section of the text is:\n\n\"Microscopy:\n\n3\\. Epidural tumor: Immunohistochemically, blastic tumor cells show a positive reaction after incubation with antibodies against CD20, PAX5 and BCL2. Partially positive reaction against Bcl-6 (<20%). Some isolated blastic cells staining positive for CD30. Lymphoid cells positive for CD3 and CD5. Some residual germinal centers with positive reaction to CD23 and CD21. Predominantly weak positive reaction of blasts and lymphoid cells to CD10. Some solitary cells with positive reaction to kappa, rather unspecific, flat reaction to lambda. No reaction to EBV/EBER. The Ki-67 proliferation index is 40%, related to blastic tumor cells > 90%.\"\n\nFrom this section, we can see that the percentage of positivity for Bcl-6 is <20%.\n\n**C**"
    },
    {
      "question_id": "patient_01_q15",
      "generated_text": "To answer this question, let's analyze the molecular pathology report for Mrs. Sample:\n\nThe report states that the DNA was isolated from the tissues and used in duplicate in specific PCRs (B-cell clonality analysis with Biomed-2 primer sets) and that the size distribution of the PCR products was further analyzed by fragment analysis. Additionally, DNA was inserted into a specific PCR to detect a BCL2/IgH fusion corresponding to a t(14;18) translocation.\n\nThe report then states that the amplification of isolated DNA was good, and B-cell clonality analyses showed a reproducible clonal signal at approximately 115/116 bp. However, the t(14;18) translocation was found to be negative.\n\nBased on this information, we can deduce that:\n\n* The sample shows no evidence of t(14;18) translocation, so option A is incorrect.\n* The report does mention the presence of clonal B-cell expansion, so option B is incorrect.\n* The report states that the t(14;18) translocation was negative, which means that option C is correct.\n* The ligament sample showed no evidence of tumor cells, so option D is incorrect.\n* The epidural tumor was identified as a DLBCL, which is a type of B-cell lymphoma, so option E is incorrect.\n\n**C**"
    },
    {
      "question_id": "patient_01_q16",
      "generated_text": "According to the text, on 01/06/2017, the immunohistochemical processing results showed that the blastic tumor cells were positive for MUM1, and numerous CD68-positive macrophages were present. There was no reaction to ALK1 and TdT. \n\nThe epidural tumor was identified as an aggressive B-non-Hodgkin lymphoma, specifically diffuse large B-cell lymphoma (DLBCL, NOS) of germinal center type.\n\nSo, the correct answer is: E"
    },
    {
      "question_id": "patient_01_q17",
      "generated_text": "To determine the correct answer, let's analyze the provided medical records and radiological examinations of Mrs. Sample.\n\nThe medical records mention several radiological examinations, but the question specifically asks about the last imaging examination. The last imaging examination mentioned in the records is an MRI of the thoracolumbar spine performed on 12/20/2016 (from text_0) and a CT thoracic spine from 01/03/2017 (from text_0).\n\nThe MRI of the thoracolumbar spine from 12/20/2016 shows a large intraspinal mass extending from T10-L1, causing an anterior spongy appearance of the spinal cord and resulting in complete spinal canal stenosis at this level.\n\nThe CT thoracic spine from 01/03/2017 shows a composite osteolytic-osteoblastic defects starting from the left pedicle in T10 and lumbar vertebra 4, and at the endplate of lumbar vertebra 2.\n\nNone of the options A, C, or D match the description of the last imaging examination mentioned in the records. Option E mentions an MRI of the head, which is not the last imaging examination mentioned.\n\nOption B, An MRI of her spine was performed, revealing a thoracic neoplastic growth primarily at the level of Th10-L1, is the correct answer as it accurately describes the MRI of the thoracolumbar spine performed on 12/20/2016.\n\n**B**"
    },
    {
      "question_id": "patient_01_q18",
      "generated_text": "To determine which parameter was elevated beyond the reference range in January 2017 for Mrs. Sample, we need to refer to the laboratory findings provided in the text. \n\nFirst, let's identify the relevant information: \n\nMetabolic Panel for January 2017:\n\n- Sodium: 136 mEq/L (Reference Range: 135 - 145 mEq/L)\n- Potassium: 3.9 mEq/L (Reference Range: 3.5 - 5.0 mEq/L)\n- Creatinine: 1.2 mg/dL (Reference Range: 0.7 - 1.3 mg/dL)\n- Alkaline Phosphatase: 138 U/L (Reference Range: 40 - 129 U/L)\n- Total Bilirubin: 0.3 mg/dL (Reference Range: < 1.2 mg/dL)\n\nNow, let's compare these values to the reference ranges to determine which parameter was elevated beyond the reference range.\n\n- Sodium is within the reference range.\n- Potassium is within the reference range.\n- Creatinine is within the reference range.\n- Alkaline Phosphatase is above the upper limit of the reference range (138 U/L > 129 U/L).\n- Total Bilirubin is within the reference range.\n\nBased on the comparison, the parameter that was elevated beyond the reference range in January 2017 is Alkaline Phosphatase.\n\n**C**"
    },
    {
      "question_id": "patient_01_q19",
      "generated_text": "To answer this question, let's consider the information provided in the text about Mrs. Sample's neurological condition.\n\n1. The text mentions that Mrs. Sample has a history of multiple sclerosis (MS) and was diagnosed with DLBCL, a type of lymphoma.\n2. After her DLBCL diagnosis, she underwent chemotherapy (R-Pola-CHP regimen) and experienced a reduction in symptoms, including discomfort in the dorsal calf and thoracic spine, and arm weakness.\n3. She also had a history of MS-related symptoms, including numbness and weakness in her legs, which persisted for several days.\n\nConsidering these points, the text does not explicitly mention \"intense and persistent spasms in both legs\" (A) or \"severe neural abnormalities\" (C) as Mrs. Sample's current neurological condition. It does mention \"mild paraparesis in the left leg\" (D) as a current neurological deficit, but it specifically states that this is in the left leg, not the right leg. Therefore, the correct answer is:\n\nB. Mild paraparesis in the right leg"
    },
    {
      "question_id": "patient_02_q0",
      "generated_text": "To answer this question, we need to refer to the text provided about patient Jane Done.\n\nStep 1: Find the relevant section about patient Jane Done.\nSection: **text_0**\n\nStep 2: Identify the relevant information about PD-L1 status.\nInformation: PD-L1 status: PD-L1 tumor proportion score (TPS): <1%.\n\nStep 3: Match the information with the options.\nOption: B. <1%\n\n**B**"
    },
    {
      "question_id": "patient_02_q1",
      "generated_text": "To determine the cumulative dose of Pembrolizumab in Mrs. Jane Done's adjuvant chemotherapy, we need to look at the text_0 and text_1 documents. \n\nIn text_0, it is mentioned that Mrs. Jane Done received 8 doses of Pembrolizumab, with each dose being 200mg. \n\nIn text_1, it is mentioned that Mrs. Jane Done received 7 doses of Pembrolizumab, with each dose being 200mg.\n\nLet's calculate the cumulative dose for both scenarios:\n\nScenario 1 (from text_0): 8 doses * 200mg/dose = 1600mg\nScenario 2 (from text_1): 7 doses * 200mg/dose = 1400mg\n\nSince we have two possible scenarios, we need to determine which one is correct. Unfortunately, the text does not provide a clear indication of which scenario is correct. However, based on the information provided, we can make an educated guess.\n\nGiven that the question asks for the cumulative dose of Pembrolizumab, and the options are in milligrams, I will choose the option that is closest to the calculated values.\n\nSince 1400mg is closer to 1.4g than 1600mg, and 1600mg is closer to 1.6g, I will choose the option that corresponds to 1.4g.\n\n**D**"
    },
    {
      "question_id": "patient_02_q2",
      "generated_text": "To determine where Mrs. Done showed metastases, let's consider the information provided in the text:\n\n1. The text mentions that Mrs. Done had a history of melanoma and underwent various treatments, including radiation therapy and immunotherapy.\n2. The PET-CT scan from 02/11/2022 showed increased FDG uptake in the lungs, indicating metastatic disease.\n3. The CT scan from 02/10/2022 revealed multiple nodular opacities across both lung fields, consistent with metastatic deposits.\n4. The CT scan also showed a cardiac mass adjacent to the left ventricle, which was suspected to be a metastasis.\n5. The CT scan further revealed lytic lesions involving the sternum and right 4th rib, consistent with osseous metastatic disease.\n6. The liver showed multiple hypodense lesions throughout both lobes, indicative of metastatic spread.\n7. The CT scan also noted retroperitoneal lymphadenopathy and a 2.5 cm mass within the left psoas muscle, consistent with muscular metastasis.\n8. The left acetabulum and the right iliac wing manifested with lytic lesions, suggesting metastatic involvement.\n\nConsidering these findings, the correct answer is:\n\n**A. brain, lungs, liver, heart, lymph nodes, muscles, bones**"
    },
    {
      "question_id": "patient_02_q3",
      "generated_text": "To determine when Mrs. Done started radiotherapy, I will look for the relevant information in the text.\n\nAccording to the text, Mrs. Done had a microsurgical resection of a right frontal mass with radiation therapy from 02-03/20. This indicates that she started radiotherapy in February 2020.\n\n**D**"
    },
    {
      "question_id": "patient_02_q4",
      "generated_text": "To determine which of the lab values were outside the reference ranges, we need to examine each value individually.\n\n1. TSH (Thyroid-Stimulating Hormone) is not mentioned in the provided text for patient ID patient_02 (Jane Done).\n2. Platelets are mentioned as 263 x10^9/L, which is within the normal range of 150-450 x10^9/L.\n3. Hemoglobin is mentioned as 12.3 g/dL, which is within the normal range of 12-16 g/dL. However, the option mentions 11.5 g/dL, which is actually the value for Hemoglobin in the previous text (text_2). So, in the provided text (text_3), Hemoglobin is actually 12.4 g/dL, which is within the normal range.\n4. GGT (Gamma-Glutamyl Transferase) is mentioned as 75 U/L, which is above the normal range of <66 U/L.\n\nGiven the information provided, the correct answer is E."
    },
    {
      "question_id": "patient_02_q5",
      "generated_text": "To determine the correct answer, let's analyze the given information:\n\n- Option A: 11 days (02/18/2018 to 03/01/2018) - This is a possible duration, but we need to check if it matches the provided information.\n- Option B: 1 month (02-03-/20) - This option is incomplete and doesn't provide a specific date range.\n- Option C: 15 days (02/14/2022 to 03/01/2022) - This option seems plausible, but we need to verify if it matches the actual duration.\n- Option D: 24 days (05/\u00df2/20 - 05/26/20) - The date \"05/\u00df2/20\" is not a valid date, making this option incorrect.\n- Option E: 14 days (03/16/2021 - 03/30/2021) - This option is a possible duration, but we need to check if it matches the provided information.\n\nGiven the options, we can see that option C, 15 days (02/14/2022 to 03/01/2022), is the most plausible answer based on the information provided in the text_4 text."
    },
    {
      "question_id": "patient_02_q6",
      "generated_text": "Let's analyze the statements step by step:\n\nA. The patient underwent a microsurgical resection for a left frontal hemorrhaged metastasis from previously diagnosed malignant melanoma on 01/20.\n\nThis statement is accurate. According to the text, on 01/02/2020, Mrs. Done had a microsurgical resection of a right frontal mass with intraoperative neuromonitoring, not left frontal.\n\nB. During one of her hospital stays, Mrs. Done was treated for a cystic metastasis, first detected in an emergency CT scan after a fall on 10/28/2020.\n\nThis statement is accurate. According to the text, on 10/28/2020, the patient had an unattended fall, resulting in a hematoma on the left forehead, and an emergency CT scan showed a cystic metastasis.\n\nC. The patient has undergone empyema removal due to an infection following her resection of a right frontal tumor, which took place in February 2020\n\nThis statement is partially accurate. According to the text, Mrs. Done underwent excision of an empyema on 02/04/2020, but it was not specified that it was due to an infection following a resection of a right frontal tumor in February 2020. However, it was mentioned that the empyema was detected after a cerebrospinal fluid (CSF) cushion was punctured, revealing the presence of pathogens.\n\nD. Mrs. Done started combination immunotherapy with 60 mg Nivolumab and 200 mg Ipilimumab on 05/26/20.\n\nThis statement is accurate. According to the text, Mrs. Done started combination immunotherapy with 60 mg Nivolumab and 200 mg Ipilimumab on 05/26/20.\n\nE. The radiation therapy delivered during her hospitalization was a hypofractionated regimen involving five sessions each delivering a dose of 8 Gy for a cumulative total dose of 40 Gy.\n\nThis statement is not accurate. According to the text, Mrs. Done underwent five sessions of radiation therapy with a cumulative total dose of 30 Gy, not 40 Gy.\n\nBased on the analysis, the correct answer is D."
    },
    {
      "question_id": "patient_02_q7",
      "generated_text": "To answer this question, I will follow the steps below:\n\n1. Identify the relevant text: The text to focus on is the PET-CT report from 02/11/2022, which is found in text_4.\n\n2. Find the specific information: In the PET-CT report, the relevant information about the lesion abutting the lateral wall of the left ventricle is found under the \"Thorax\" section.\n\n3. Extract the SUVmax value: The SUVmax value for the lesion is mentioned as 9.5.\n\nTherefore, the correct answer is: \nC"
    },
    {
      "question_id": "patient_02_q8",
      "generated_text": "To determine the correct answer, let's follow the steps:\n\n1. The patient, Jane Done, was diagnosed with metastatic malignant melanoma.\n2. The question mentions that Mrs. Done's molecular profile revealed the presence of a specific mutation.\n3. The recommended therapeutic combination includes Vemurafenib and Cobimetinib, both of which are targeted therapies.\n4. Vemurafenib and Cobimetinib are known to target the BRAF-MEK signaling pathway.\n5. The BRAF V600E mutation is a specific mutation that leads to the constitutive activation of the BRAF protein, which is a key component of the BRAF-MEK signaling pathway.\n6. The presence of the BRAF V600E mutation in Mrs. Done's molecular profile makes her a suitable candidate for treatment with Vemurafenib and Cobimetinib.\n\n**C**"
    },
    {
      "question_id": "patient_02_q9",
      "generated_text": "To determine the correct answer, let's analyze the treatment regimen mentioned for Mrs. Done:\n\nThe treatment regimen includes Pembrolizumab, Nivolumab, and Ipilimumab. Pembrolizumab is an immunotherapy that can cause immune-related adverse events, including hypothyroidism, adrenal insufficiency, and increased liver enzymes. However, it does not directly cause fever or changes in blood pressure or blood glucose levels.\n\nNivolumab is an immune checkpoint inhibitor that can cause fatigue, rash, and diarrhea, but it is not typically associated with fever, hypertension, or hyperglycemia.\n\nIpilimumab is another immune checkpoint inhibitor that can cause colitis, dermatitis, and endocrinopathies, including hypothyroidism and adrenal insufficiency. However, it is not typically associated with fever, hypertension, or hyperglycemia.\n\nConsidering the treatment regimen, the parameter that warrants immediate medical attention is a fever exceeding 38.3\u00b0C, as it could be a sign of an immune-related adverse event, such as cytokine release syndrome.\n\n**B**"
    },
    {
      "question_id": "patient_02_q10",
      "generated_text": "To answer this question, I will follow these steps:\n\n1. Identify the patient: Jane Done\n2. Identify the relevant section in the text: Macroscopy report\n3. Find the relevant information: Resection margins to the tumor\n4. Determine the closest approach of the resection margins to the tumor\n\nFrom the provided text, I found the relevant information in the section labeled \"Macroscopy\" in the text_3 section:\n\n\"Resection margins are mostly free of tumor, with the closest approach being less than 0.15 cm (points 2 and 3).\"\n\nTherefore, the correct answer is:\n\nB"
    },
    {
      "question_id": "patient_02_q11",
      "generated_text": "To answer this question, we need to compare the SARS-CoV-2 PCR results from admission and discharge.\n\nUpon admission, Mrs. Jane Done's SARS-CoV-2 PCR results were:\n\n- Viral load: 7,000 Geq/mL\n- Ct value: 32\n\nAt discharge, her SARS-CoV-2 PCR results were:\n\n- Viral load: 2,350 Geq/mL\n- Ct value: 32\n\nGiven this information, we can see that the viral load decreased (from 7,000 Geq/mL to 2,350 Geq/mL), but the Ct values remained the same (32).\n\nSo, the correct answer is: \nC"
    },
    {
      "question_id": "patient_02_q12",
      "generated_text": "To answer this question, we'll go through the steps of the neck dissection procedure performed on Mrs. Done on 01/05/2021.\n\n1. The surgical area was washed and sterilized, focusing on the pre-existing access point.\n2. A team time-out was conducted.\n3. Perioperative antibiotics were withheld until all samples for microbiology were obtained.\n4. The skin was incised, revealing multiple layers of muscle.\n5. These were carefully dissected, leading to the identification and evacuation of the subcutaneous epifascial abscess.\n6. Infected muscle tissue and abscess walls were resected.\n7. The skull flap appeared loosened.\n8. A miniplate was removed, and upon further inspection, the dura mater appeared strained.\n9. It was incised and revealed turbid fluid, indicating a deep abscess.\n10. The dura mater was mobilized, though adherence to the cortex was observed around the resection cavity, suggesting possible tumor regrowth.\n11. Affected areas were carefully resected.\n12. After thorough irrigation, a drainage system was inserted into the resection cavity.\n13. A duraplasty was performed, followed by the reimplantation of the bone flap using a miniplate.\n14. The patient was also included in a bone flap study and was randomized for flap reimplantation.\n15. After further irrigation, the wound was meticulously closed, and a subfascial drain was inserted.\n\nNow, considering the steps mentioned above, let's analyze the surgical steps taken during the neck dissection procedure:\n\n- The text does not explicitly state that the auricularis magnus nerve was severed or preserved.\n- It does mention the identification and preservation of the trapezoid branch of the accessory nerve during the procedure.\n- The accessory nerve was identified and preserved.\n\nTherefore, the correct answer is:\n\nC"
    },
    {
      "question_id": "patient_02_q13",
      "generated_text": "To find the correct answer, let's look for the key information about the initial procedure performed for Mrs. Jane Done in February 2018.\n\n1. The initial diagnosis is mentioned as \"Malignant melanoma, left upper back\" in the text_0 section.\n2. The procedure details for the initial diagnosis are described in the \"Operation report from 02/22/2018\" section.\n3. According to this report, the procedure was an \"excision of malignant melanoma on the left upper back.\"\n\nTherefore, the correct answer is:\n\nB"
    },
    {
      "question_id": "patient_02_q14",
      "generated_text": "To determine which medication was given to Mrs. Done for eczema treatment during her hospital stay from 10/23/2020 to 11/01/2020, let's analyze the information provided.\n\nThe patient was admitted to the hospital with a history of multiple skin changes on her right arm, which were suspicious for malignancy. The patient was treated for eczema with the following medications:\n\n1. Topical Treatment for Eczema: Applied Desonide Cream once daily to the affected areas.\n2. Antipruritic Treatment: Prescribed Benadryl tablets, to be taken as needed.\n\nHowever, the question specifically asks about the medications given during the hospital stay from 10/23/2020 to 11/01/2020. The treatment for eczema mentioned above does not include any oral medications, but it does mention topical treatment with Desonide Cream.\n\nLooking at the options provided:\n\nA. Paracetamol - This is an analgesic and antipyretic medication, not related to eczema treatment.\nB. Pembrolizumab - This is an immunotherapy medication, not related to eczema treatment.\nC. Desonide Cream - This is the correct medication mentioned in the text as a topical treatment for eczema.\nD. Levothyroxine - This is a medication for hypothyroidism, not related to eczema treatment.\nE. Calcium Supplement - This is a supplement for calcium deficiency, not related to eczema treatment.\n\n**C**"
    },
    {
      "question_id": "patient_02_q15",
      "generated_text": "To answer this question, I will follow these steps:\n\n1.  Look for the relevant information in the provided text about patient ID patient_02, which is actually named Mrs. Done, and her diagnosis of melanoma.\n2.  The relevant information is found in the text \"text_0\" where the histopathological diagnosis of the excised melanoma is described.\n3.  The description of the histopathological findings mentions that the tumor shows stages E, F, G, and H, which are described as an exophytic, bovist-like growing ulcerated hemorrhagic tumor consisting of completely pleomorphic tumor cells.\n4.  The tumor cells are described as having hyperchromatic nuclei with coarse-grained chromatin and a narrow cytoplasmic border, and there are also blastic cells with enlarged nuclei, vesicular chromatin, and sometimes prominent nucleoli.\n5.  The stroma is described as loose and vacuolated, and there are pronounced crush artifacts.\n6.  Based on these findings, the diagnosis is described as an exophytic, ulcerated malignant melanoma with a tumor thickness of at least 15 mm.\n\nTherefore, the correct answer is:\n\nD. Exophytic, ulcerated malignant melanoma with a tumor thickness of at least 15 mm"
    },
    {
      "question_id": "patient_02_q16",
      "generated_text": "To determine the correct answer, let's break down the information provided in the MRI brain report dated 01/04/2020.\n\nThe report states that there is evidence of a right frontotemporal craniotomy with associated post-surgical changes in the right frontal region. It also mentions that the previous tumor site in the right frontal lobe shows post-surgical changes with a well-circumscribed cavity. There is no evidence of residual enhancing tumor within this cavity on post-contrast sequences, suggesting complete resection.\n\nConsidering this information, the correct answer is:\n\nD"
    },
    {
      "question_id": "patient_02_q17",
      "generated_text": "To answer this question, let's analyze the events that occurred during Mrs. Done's stay from 10/23/2020 to 11/01/2020.\n\n1. The patient had an unattended fall, resulting in a hematoma on the left forehead. This is a significant incident that occurred on 10/28/2020.\n2. There is no mention of the patient developing a drug exanthema, starting Nivolumab and Ipilimumab therapy, being diagnosed with hydrocephalus, or being diagnosed with empyema in relation to this specific time period.\n\nGiven this information, the correct answer is:\n\nC"
    },
    {
      "question_id": "patient_02_q18",
      "generated_text": "To answer this question, we need to refer to the PET/CT findings mentioned in the text for Mrs. Done.\n\nAccording to the PET/CT findings, the right Level II, right Level III, left Level II, left Level IV, and retropharyngeal space showed increased FDG uptake consistent with metastatic disease. However, the left Level III is not mentioned as showing increased FDG uptake.\n\nSo, the correct answer is:\n\nB"
    },
    {
      "question_id": "patient_02_q19",
      "generated_text": "To determine Mrs. Done's lab results for Hemoglobin upon discharge, I will refer to the provided texts.\n\nFrom text_1, under the section \"Lab values at discharge:\", we can find the lab results for Mrs. Done upon discharge. Specifically, under the section \"Complete Blood Count\", the result for Hemoglobin is listed as 12.4 g/dL.\n\nSo, the correct answer is: \nB"
    },
    {
      "question_id": "patient_03_q0",
      "generated_text": "To answer this question, I need to refer to the provided text and find the relevant information about Mr. John Williams' diagnosis and treatment.\n\nFrom the text, I see that Mr. John Williams was diagnosed with Multiple Myeloma in 2015. In the section about his treatment, I find the following information:\n\n\"CT whole body 03/11/2015: Osteolysis detected in the seventh thoracic vertebra (T7); pathologic fracture observed in the first lumbar vertebra (L1).\"\n\nBased on this information, I can conclude that osteolysis was detected in the seventh thoracic vertebra (T7) and the first lumbar vertebra (L1).\n\nSo, the correct answer is:\n\nD. B and C"
    },
    {
      "question_id": "patient_03_q1",
      "generated_text": "To determine which treatment resulted in prolonged pancytopenia for Mr. Williams, we need to analyze the information provided in the text.\n\nFirst, let's look at the treatment options:\n\nA. Cyclophosphamide, bortezomib, and dexamethasone\nB. Combination of carfilzomib, lenalidomide, and dexamethasone\nC. Stem cell mobilization using cyclophosphamide\nD. Cyclophosphamide\u2013carfilzomib\u2013dexamethasone\n\nWe can see that all of these options involve cyclophosphamide, which is a chemotherapy drug known to cause pancytopenia as a side effect. However, we need to determine which one resulted in prolonged pancytopenia for Mr. Williams.\n\nAccording to the text, Mr. Williams experienced prolonged pancytopenia after receiving 2 cycles of Cyclophosphamide-Bortezomib-Dexamethasone (CyBorD). This suggests that option A is the correct answer.\n\nHowever, we also need to consider option D, which includes cyclophosphamide. But the text does not mention that the combination of cyclophosphamide, carfilzomib, and dexamethasone resulted in prolonged pancytopenia.\n\nConsidering the information provided, the correct answer is:\n\nA"
    },
    {
      "question_id": "patient_03_q2",
      "generated_text": "To answer this question, let's break it down step by step.\n\n1. The question is about immunohistochemical findings in Mr. Williams, specifically regarding the percentage of blast cells positive for CD34 and CD117.\n2. The relevant text is from \"text_1\" in the provided text, under the section \"Immunohistochemical Additional Findings (Dated 10/04/2015):\"\n3. The text states: \"Immunohistochemistry Stains Used: CD3, CD79a, CD34, CD117, MUM-1, Kappa, lambda, CyclinD1, CD61.\"\n4. It also states: \"Blast cells positive for CD34 and CD117 are below 5% of the total.\"\n5. Therefore, the percentage of blast cells positive for CD34 and CD117 is below 5%.\n\n**E**"
    },
    {
      "question_id": "patient_03_q3",
      "generated_text": "To answer this question, let's analyze the information provided about Mr. Williams' PSMA-PET-CT scan results.\n\nThe text mentions that the PSMA-PET-CT scan showed increased PSMA uptake in various areas, but it specifically highlights the following:\n\n* A lytic lesion involving the sternum and right 4th rib, consistent with osseous metastatic disease.\n* A mass in the head of the pancreas with contact to the SMV (approximately 90 degrees) and suspected lymph node metastasis near the SMA.\n* No evidence of primary malignancy in the previously mentioned mixed osteoblastic/osteolytic lesions in the vertebra.\n\nGiven this information, we can infer that the PSMA-PET-CT scan primarily highlighted metastatic disease in the thoracic spine, sternum, and pancreas. However, the question specifically asks about the vertebra with the most notable PSMA uptake.\n\nSince there is no direct mention of PSMA uptake in the vertebrae in the provided text, we can make an educated guess based on the information given.\n\nA notable PSMA uptake was observed in the lytic lesion involving the sternum and right 4th rib, which implies that the 4th rib showed significant PSMA uptake.\n\nConsidering the options provided:\n\nA. C4 - Not mentioned\nB. L1 - Not mentioned\nC. Th4 - Not mentioned, but the 4th rib was involved\nD. Th7 - Not mentioned\nE. L5 - Not mentioned\n\nBased on the given information, the most likely answer is C. Th4, as the 4th rib was involved in the lytic lesion with notable PSMA uptake.\n\n**C**"
    },
    {
      "question_id": "patient_03_q4",
      "generated_text": "To answer this question, let's analyze the given text from patient_0, which contains information about Mr. Williams' medical history and treatments.\n\nThe relevant text is:\n\n\"CT Thoracic Spine from 01/03/2017\n\n[Clinical Findings]{.underline}\n\nLateral and medial alignment is stable. No sign of vertebral column damage. Multiple segment degenerative alterations in the spine. No indications of mineralization in the recognized space at the level of T10/L2. Invasion of T10 and L4 with composite osteolytic-osteoblastic defects starting from the left pedicle into the vertebral column. More cortical inconsistency with enhanced sclerosis at the endplate of L2. Review with prior MRI indicative of a different composite defect. Defect pit at the endplate of lumbar vertebra 2.\n\nMinor pericardial effusion with nearby superior ventilation. Intubation tube placed. Mild cardiomediastinum. Splenomegaly. Standard display of the tissue organs of the mid-abdomen, as naturally observed. Normal spleen. Thin adrenals. Tightly raised kidney bowls and leading ureter from both aspects, e.g., upon entry during the exhalation period after gadolinium inclusion in the earlier MRI. No bowel obstruction. Intestinal stasis. No sign of abnormally magnified lymphatic vessels. Remaining pin holes in the femoral head on both sides.\n\n[Evaluation]{.underline}\n\nComposite osteolytic-osteoblastic defects starting from the left pedicle in T10 and lumbar vertebra 4, and at the endplate of lumbar vertebra 2.\"\n\nHowever, this text does not mention the specific contrast agent used for the CT scan on 01/09/2017.\n\nWe need to look at another text, patient_1, which contains more information about Mr. Williams' medical history and treatments.\n\nThe relevant text is:\n\n\"**CT Chest/Abdomen/Pelvis + Contrast from 01/09/2017**\n\nResults: After uneventful intravenous administration of Omnipaque 320, a multi-slice helical CT of the chest, abdomen, and pelvis was performed during the venous phase of contrast enhancement. Additional oral contrast was given using Gastrografin (diluted 1:35). Thin slice reconstructions were obtained, along with secondary coronal and sagittal reconstructions.\"\n\nBased on this text, the correct answer is:\n\nA"
    },
    {
      "question_id": "patient_03_q5",
      "generated_text": "Let's analyze the radiologic examinations mentioned for Mr. John Williams:\n\n1. CT Whole Body (03/11/2015)\n2. MR Spine Scan (not specified date)\n3. CT Spine Scan (12/01/15)\n4. PSMA-PET-CT Scan (05/2018)\n5. CT Chest (12/02/15 and 12/03/15)\n6. Whole Body CT scan (not specified date)\n7. CT Whole Body (not specified date)\n\nFrom the text, we can deduce the order of the examinations based on the dates provided:\n\n- The first CT Whole Body scan was performed on 03/11/2015.\n- The CT Spine Scan was performed on 12/01/15.\n- The CT Chest scan was performed on 12/02/15 and 12/03/15.\n- The PSMA-PET-CT Scan was performed on 05/2018.\n\nHowever, the text does not provide the exact dates for the MR Spine Scan and the second CT Whole Body scan. Based on the context, it is likely that the MR Spine Scan was performed before the second CT Whole Body scan, as the second CT Whole Body scan is mentioned after the MR Spine Scan in option E. \n\nSo, the most logical order is:\n\nWhole Body CT scan > CT Spine Scan > CT Chest > PSMA-PET-CT Scan > MR Spine Scan > CT Whole Body\n\n**E**"
    },
    {
      "question_id": "patient_03_q6",
      "generated_text": "To determine the correct answer, let's analyze the text and identify the changes in Mr. Williams' medications between 2018 and March 2019.\n\nIn the text, it is mentioned that Mr. Williams underwent stem cell mobilization due to RSV pneumonia complications and then started on Daratumumab monotherapy. The treatment plan mentioned includes Daratumumab s.c. 1800mg abs. weekly in week 1-8, 2-weekly in week 9-24, every 4 weeks from week 25. It is also mentioned that Lenalidomide 5 mg was part of the treatment plan, but it was given only on days 1-21.\n\nIn March 2019, Mr. Williams underwent mobilization chemotherapy with cyclophosphamide, with a dosage adjusted due to his requirement for dialysis. The medications listed at that time include:\n\n  **Medication**                  **Dosage**         **Frequency**\n  ------------------------------- ------------------ ------------------------------------\n  Fentanyl Patch (Duragesic)      25 \u03bcg              Change every 72 hours\n  Enoxaparin (Lovenox)            0.2 mL             Nightly (dialysis dose)\n  Dexamethasone (Decadron)        8 mg               Morning on 03/05 & 03/06\n  Pantoprazole (Protonix)         40 mg              Morning\n  Cotrimoxazole (Bactrim Forte)   480 mg             Morning 3x weekly on Mon, Wed, Fri\n  Valacyclovir (Valtrex)          500 mg             Half tablet in the morning\n  Ibandronate (Boniva)            2 mg               Every 4 weeks\n  Leuprorelin (Lupron Depot)      3.75 mg            Monthly subcutaneously\n  Pregabalin (Lyrica)             25 mg              Morning and Evening\n  Amlodipine (Norvasc)            5 mg               Daily in the morning\n  Bisoprolol (Zebeta)             2.5 mg             Morning and Evening\n  Filgrastim (Neupogen/Granix)    48 million IU      Morning and Evening\n\nLooking at the medications listed for March 2019, we can see that:\n\n- Lenalidomide 5 mg is not listed as a daily medication, but it is mentioned that Lenalidomide 5 mg from day 1-21 was part of the treatment plan.\n- Bisoprolol 2.5 mg is listed as a medication that Mr. Williams is taking.\n- Pregabalin (Lyrica) 25 mg is listed as a medication that Mr. Williams is taking in the morning and evening.\n\nGiven this information, the correct answer is B. The patient started taking Lyrica 25 mg and Lenalidomide 5 mg nightly.\n\n**B**"
    },
    {
      "question_id": "patient_03_q7",
      "generated_text": "To determine the correct answer, let's compare the medication lists between the first and last recorded medication for Mr. John Williams.\n\nThe first recorded medication list is from March 2019:\n\n  **Medication**                 **Dosage**         **Frequency**\n  ------------------------------ ------------------ ------------------------------------\n  Fentanyl Patch (Duragesic)      25 \u03bcg              Changed every 72 hours\n  Enoxaparin (Lovenox)            0.2 mL             Nightly (dialysis dose)\n  Dexamethasone (Decadron)        8 mg               Morning on 03/05 & 03/06\n  Pantoprazole (Protonix)         40 mg              Daily in the morning\n  Cotrimoxazole (Bactrim)         480 mg             Morning 3x weekly on Mon, Wed, Fri\n  Valacyclovir (Valtrex)          500 mg             Half tablet in the morning\n  Ibandronate (Boniva)            2 mg               Every 4 weeks\n  Leuprorelin (Lupron Depot)      3.75 mg            Monthly subcutaneously\n  Pregabalin (Lyrica)             25 mg              Morning and Evening\n  Amlodipine (Norvasc)            Currently paused    Currently paused\n  Bisoprolol (Zebeta)             2.5 mg             Morning and Evening\n  Filgrastim (Neupogen/Granix)    48 million IU      Morning and Evening\n\nThe last recorded medication list is from September 2021:\n\n  **Medication**                  **Dosage**         **Frequency**\n  ------------------------------- ------------------ ------------------------------------\n  Fentanyl Patch (Duragesic)       25 \u03bcg              Changed every 72 hours\n  Enoxaparin (Lovenox)            0.2 mL             Nightly (dialysis dose)\n  Dexamethasone (Decadron)        8 mg               Morning on 09/04 & 09/05\n  Pantoprazole (Protonix)         40 mg              Daily in the morning\n  Cotrimoxazole (Bactrim)         960 mg             Daily on Mondays, Wednesdays, and Fridays\n  Valacyclovir (Valtrex)          500 mg             Daily\n  Ibandronate (Boniva)            2 mg               Every 4 weeks\n  Leuprorelin (Lupron Depot)      3.75 mg            Every 4 weeks\n  Pregabalin (Lyrica)             25 mg              Morning and Evening\n  Amlodipine (Norvasc)            5 mg               Daily\n  Bisoprolol (Zebeta)             2.5 mg             Daily\n  Filgrastim (Neupogen/Granix)    48 million IU      Morning and Evening\n\nComparing the two lists, we can see that:\n\n- Pantoprazole's dosage remained the same.\n- Valtrex's dosage increased from half a tablet to a full tablet (500 mg) and was taken daily instead of half a tablet in the morning.\n- Bactrim's dosage increased from three times a week to daily.\n- Lovenox's frequency remained the same.\n- Tamsulosin's dosage was not adjusted to 0.8mg daily.\n- Plavix's dosage was not adjusted to twice daily.\n\nBased on these changes, the correct answer is:\n\n**D**"
    },
    {
      "question_id": "patient_03_q8",
      "generated_text": "Let's analyze the sequence of events for Mr. John Williams.\n\n- Mr. Williams had a mitral valve reconstruction via minithoracotomy in 2015 (text_2).\n- The first diagnosis of multiple myeloma was in 2015 (text_1 and text_2).\n- The prostate carcinoma diagnosis was in January 2018 (text_2 and text_3).\n- Acute mitral valve endocarditis occurred in March 2020 (text_8).\n\nConsidering these events, the correct sequence is: First diagnosis of multiple myeloma in 2015, mitral valve reconstruction in 2015, prostate carcinoma diagnosis in January 2018, and then acute mitral valve endocarditis in March 2020.\n\n**E**"
    },
    {
      "question_id": "patient_03_q9",
      "generated_text": "Let's break down the treatment chronology for Mr. John Williams based on the provided information:\n\n1. Mr. Williams was initially treated with Bortezomib and Dexamethasone in 2015, but this treatment was not effective and was later replaced.\n2. In 2018, he received radiation to Th4 and the thoracic rib in August, which is correct.\n3. Between August and October 2018, he underwent three cycles of Pomalidomide, Doxorubicin, and Dexamethasone, which is also correct.\n4. In November 2018 to February 2019, he received four treatments of Daratumumab, Lenalidomide, and Dexamethasone, which is correct.\n5. In March 2019, he underwent stem cell mobilization due to RSV pneumonia complications, but the treatment details for this period are not specified.\n6. The information about pausing Daratumumab in November 2019 due to remission and then escalating therapy to include Daratumumab, Revlimid, and Dexamethasone in July 2020 is not mentioned in the provided text.\n7. The information about pausing Daratumumab until March 2020 due to remission and a diagnosis of endocarditis is not mentioned in the provided text.\n\nBased on the provided information, the correct sequence of events is:\n\nReceived radiation to Th4 and the thoracic rib in August 2018, underwent three cycles of Pomalidomide, Doxorubicin, and Dexamethasone between August and October 2018, and then received four treatments of Daratumumab, Lenalidomide, and Dexamethasone from November 2018 to February 2019.\n\n**B**"
    },
    {
      "question_id": "patient_03_q10",
      "generated_text": "To answer this question, let's review the patient's history and examinations mentioned in the text.\n\n1. **Whole spine MRI**: This examination was performed on multiple occasions, including 06/20/2018, to evaluate the extent of bone lesions in Mr. Williams' multiple myeloma.\n2. **Ophthalmological exams**: The text mentions that eye examinations were conducted to evaluate vision issues, potentially stemming from the mitral valve endocarditis, but it does not specify the exact date or details of these exams.\n3. **Bone marrow aspiration**: This examination was performed in 2015 to assess the extent of bone marrow infiltration by plasma cells in Mr. Williams' multiple myeloma.\n4. **Echocardiography**: This examination was performed on multiple occasions, including 01/12/2022, to evaluate the patient's heart function, particularly after the development of congestive heart failure.\n5. **Cardiac stress test**: There is no mention of a cardiac stress test being performed on Mr. Williams in the provided text.\n\nGiven this information, I would guess that the examination that was never performed in Mr. Williams is:\n\nE"
    },
    {
      "question_id": "patient_03_q11",
      "generated_text": "Let's analyze the information provided for Mr. John Williams:\n\n1. Mr. Williams was diagnosed with Multiple Myeloma in 2015, not 2020.\n2. He underwent stem cell mobilization due to complications from RSV pneumonia, not due to RSV pneumonia in March 2019.\n3. The statement about VGPR being noted in May 2018 is not mentioned, but it is mentioned that he had a very good partial response (VGPR) in March 2019.\n4. The statement about Mr. Williams presenting with symptoms in November 2022 is accurate, and the preliminary findings include a reduced LVEF of 35%, elevated BNP levels, and an echocardiogram showing mild mitral regurgitation.\n5. The statement about the increase in LK values and the resumption of Daratumumab is not mentioned in the provided text for patient ID 03.\n6. Mr. Williams received radiation to the T4 and rib thorax, but the total dose is not specified, not totaling 20 Gy each.\n\nBased on this analysis, the correct answer is:\n\nC"
    },
    {
      "question_id": "patient_03_q12",
      "generated_text": "Let's analyze the information provided in the text about Mr. John Williams' treatment in August 2018.\n\nFrom the text, we can see that in August 2018, Mr. Williams received radiation therapy to the T4 and thoracic rib (option B). \n\nThe text also mentions that in July 2018, he was diagnosed with prostate carcinoma and was treated with an androgen blockade using Enantone (option E).\n\nThere is no mention of Daratumumab, lenalidomide, and dexamethasone in August 2018 (option A), or mobilization chemotherapy with cyclophosphamide in August 2018 (option D).\n\nTherefore, the correct answer is B."
    },
    {
      "question_id": "patient_03_q13",
      "generated_text": "To determine the correct answer, let's break down the information provided:\n\n1. The patient, Mr. John Williams, was admitted to the hospital from March 1, 2019, to March 3, 2019.\n2. The patient had a history of multiple myeloma, diagnosed in 2015, with various treatments including Bortezomib and Dexamethasone, Carfilzomib, Lenalidomide, and Dexamethasone, and radiation therapy to Th4 of the rib thorax.\n3. The patient had undergone stem cell mobilization due to RSV pneumonia complications and was then started on Daratumumab monotherapy (VGPR was last noted in May 2018).\n4. The patient had a recent CT scan that showed no new osteolyses.\n5. The patient had a follow-up with his nephrologist due to chronic renal insufficiency.\n\nGiven this information, the tumor board's decision on March 3, 2019, would likely focus on the patient's current condition and the effectiveness of his current treatment.\n\nBased on the provided text, it seems that the patient had a good partial response (VGPR) with Daratumumab monotherapy and had undergone stem cell mobilization. The decision would likely aim to continue this effective treatment plan.\n\nConsidering the options provided:\n\n- Option A: Continue with daratumumab, Revlimid, and dexamethasone and undergo stem cell mobilization with autologous stem cell transplant. This option aligns with the patient's recent good response to Daratumumab monotherapy and the fact that he had undergone stem cell mobilization.\n\n- Option B: Begin treatment with Enantone for prostate carcinoma. There is no mention of the patient's prostate carcinoma treatment in the provided text.\n\n- Option C: Initiate radiation therapy to Th4 of the rib thorax. The patient had already undergone radiation therapy to Th4 of the rib thorax in August 2018.\n\n- Option D: Switch to VelDex due to his renal function. There is no mention of switching the patient's treatment to VelDex due to his renal function.\n\n- Option E: Continue with carfilzomib, lenalidomide, and dexamethasone. The patient had already received this treatment, and it was not mentioned as an option for future treatment.\n\nBased on the information provided, the most likely decision of the tumor board on March 3, 2019, would be to continue the patient's current treatment plan.\n\n**A**"
    },
    {
      "question_id": "patient_03_q14",
      "generated_text": "To determine which imaging method and findings provided evidence of Mr. Williams's metastatic involvement at the level of T4 vertebral body consistent with prostate cancer, we need to analyze each option:\n\nA. A CT Spine scan on 09/30/2018 showed extensive osteolysis in multiple vertebral bodies, but it does not specifically mention the level of T4 or metastatic involvement consistent with prostate cancer.\n\nB. An MRI of the entire spine on 06/20/2018 revealed disseminated bone lesions throughout the spine without any soft tissue involvement, but it does not specifically mention metastatic involvement at the level of T4 or consistent with prostate cancer.\n\nC. A PSMA-PET-CT Scan in 05/2018 showed notably increased PSMA uptake at the level of T4 vertebral body, indicating evidence of metastatic involvement. This option is consistent with prostate cancer, as PSMA (Prostate-Specific Membrane Antigen) is a marker commonly used to detect prostate cancer.\n\nD. A bone marrow biopsy indicating interstitial and focal nodular invasion of the marrow space by plasma cell myeloma is related to multiple myeloma, not prostate cancer.\n\nE. A radio-oncological assessment scheduled for 09/05/2018 to check the effects of radiation therapy does not provide any findings or evidence of metastatic involvement at the level of T4 vertebral body consistent with prostate cancer.\n\nBased on the analysis, the correct option is:\n\nC"
    },
    {
      "question_id": "patient_03_q15",
      "generated_text": "To determine which treatment combination Mr. Williams was on, let's analyze the provided information.\n\nFrom the text, we can see that Mr. Williams was diagnosed with Multiple Myeloma and underwent various treatments. The relevant information for this question is from the text \"text_7\" and \"text_8\".\n\nIn \"text_7\", it is mentioned that Mr. Williams was treated with:\n\n- Daratumumab\n- Revlimid (Lenalidomide)\n- Dexamethasone\n\nIn \"text_8\", it is mentioned that Mr. Williams was on Daratumumab, Lenalidomide, and Dexamethasone.\n\nBased on this information, we can conclude that Mr. Williams was on a treatment combination that includes Daratumumab, Lenalidomide, and Dexamethasone.\n\nNow, looking at the options provided:\n\nA. Velcade, Dexamethasone, and Enantone. (Enantone is an androgen receptor antagonist, which is not related to Multiple Myeloma treatment)\n\nB. Velcade, Daratumumab, and Bondronate. (This option includes Daratumumab, which matches the treatment combination mentioned)\n\nC. Velcade, Dexamethasone, and Lenalidomide. (This option includes Lenalidomide, but the other two drugs are not part of the combination mentioned)\n\nD. Velcade, Cotrim forte, and Novalgin. (Cotrim forte and Novalgin are not related to Multiple Myeloma treatment)\n\nE. Velcade, Daratumumab, and Clexane. (Clexane is a blood thinner, which is not related to Multiple Myeloma treatment)\n\nBased on the information provided, the correct answer is:\n\n**B.**"
    },
    {
      "question_id": "patient_03_q16",
      "generated_text": "To answer this question, let's analyze the microscopic examination of Mr. Williams' bone marrow biopsy:\n\n1. The microscopic examination shows a normocellular bone marrow with a relative increase in erythropoiesis, which means option A (Increased erythropoiesis) is observed.\n2. The examination also reveals evidence of bone marrow edema and enhanced hemosiderosis, which means options B (Enhanced hemosiderosis) and C (Evidence of bone marrow edema) are observed.\n3. Scattered mature plasma cells are observed, but there is no mention of atypical proliferation of plasma cells, which means option D (Atypical proliferation of plasma cells) is NOT observed.\n4. The examination also mentions that the cellularity is around 20-30%, which is considered normocellular for the patient's age, which means option E (Normocellular medullary canals) is observed.\n\nSo, the correct answer is:\n\nD"
    },
    {
      "question_id": "patient_03_q17",
      "generated_text": "To determine which treatment was administered to Mr. Williams in the period 03/15 - 06/15, we can look at the provided text. \n\nIn the text, under the section \"Treatment Timeline\" for Mr. Williams, we can see that the treatment administered from 01-02/15 was Cyclophosphamide-Bortezomib-Dexamethasone. However, this is not within the specified time period of 03/15 - 06/15.\n\nLooking further, we can see that the treatment administered from 03/15 - 06/15 is listed as Carfilzomib, Lenalidomide, and Dexamethasone.\n\nSo, the correct answer is B."
    },
    {
      "question_id": "patient_03_q18",
      "generated_text": "To answer this question, we need to look at the FISH results mentioned in the text. \n\nAccording to the text, the FISH results in 03/2015 showed an additional signal for both CCND1 and CCND3. Additionally, the presence of one trisomy or tetrasomy 9 was detected. The text also mentions additional signals on chromosomes 5 and 19, but it does not specify the exact nature of these signals.\n\nBased on this information, we can rule out options C and D because the text states that there are additional signals for CCND1 and 5p15- and 5q31-. We can also rule out option E because the text does not mention the ASxL1 mutation.\n\nBetween options A and B, the text only mentions the presence of one trisomy or tetrasomy 9, so we can rule out option B.\n\nTherefore, the correct answer is:\n\nA"
    },
    {
      "question_id": "patient_03_q19",
      "generated_text": "To determine the correct answer, let's review the provided text and analyze the complications experienced by Mr. Williams:\n\n- The text mentions that Mr. Williams underwent various treatments for his multiple myeloma, including chemotherapy and stem cell mobilization.\n- It also mentions that he experienced complications such as mucositis, central line infection, gastrointestinal symptoms, urinary infections with E. faecium and E.coli, and JC virus bladder infection.\n\nBased on the information provided, we can see that Mr. Williams experienced mucositis, gastrointestinal symptoms, E. faecium infection, and JC virus bladder infection as complications.\n\nHowever, there is no mention of pulmonary embolism as a complication experienced by Mr. Williams.\n\nTherefore, the correct answer is:\n\nE"
    },
    {
      "question_id": "patient_04_q0",
      "generated_text": "To answer this question, let's look at the provided text for patient_04.\n\nThe relevant information is found in the text: \"She reported changes in bowel habits with fatty stools and pale stools starting in July 2021, and has lost approximately 3 kg since then. She denied any signs of bleeding. She had no urinary symptoms but did note that her urine had been darker than usual. In August 2021, she first noticed yellowing of the eyes and skin.\"\n\nBased on this information, Mrs. Jill Anderson first noticed scleral and cutaneous icterus in August 2021.\n\n**B**"
    },
    {
      "question_id": "patient_04_q1",
      "generated_text": "To answer this question, let's go through each option one by one and see if it is associated with Mrs. Anderson's visits in the described records.\n\nA. Luxation of the shoulder joint: This is mentioned in the record dated 07/08/2014, where it says \"Dislocation of the shoulder.\"\n\nB. Fracture tuberculum majus humeri: This is mentioned in the record dated 2014, where it says \"Fracture tuberculum majus humeri.\"\n\nC. Ankle sprain on the right side: This is mentioned in the record dated 02/01/2015, where it says \"Right foot: Swelling and pressure pain over the fibulotalar anterior ligament.\"\n\nD. Mild skin itching: This is mentioned in the record dated 09/28/2021, where it says \"Scleral and cutaneous icterus. Mild skin itching.\"\n\nE. Fracture of the right wrist: There is no mention of a fracture of the right wrist in the provided records.\n\nTherefore, the correct answer is:\n\nE"
    },
    {
      "question_id": "patient_04_q2",
      "generated_text": "To answer this question, let's analyze the information provided in the text.\n\nThe text mentions that Mrs. Anderson was admitted to the hospital on 09/28/21 for ERCP and endoscopic ultrasound-guided biopsy due to an unclear mass in the head of the pancreas. On 09/29/21, she underwent ERCP and stenting of the bile duct, and the procedure included metal stent insertion.\n\nThe text also mentions that a tumor board discussion on 09/30/21 recommended port placement and neoadjuvant chemotherapy with FOLFIRINOX.\n\nGiven this information, we can infer that on 09/29/21, Mrs. Anderson underwent an ERCP and stenting procedure, which involved metal stent insertion, but there is no clear indication of the other procedures mentioned in the options.\n\nHowever, considering the options provided and the information given, the most relevant procedure on 09/29/21 is the ERCP and stenting of the bile duct, which involved metal stent insertion, but this option is not directly mentioned in the provided choices.\n\nGiven the available options, the closest match would be B. Endoscopic ultrasound-guided FNA, as it is the only option that is related to the procedures mentioned on 09/29/21.\n\n**B**"
    },
    {
      "question_id": "patient_04_q3",
      "generated_text": "Based on the CT scan findings on 09/28/21, I will analyze the information step by step:\n\n1. The CT scan of the chest and abdomen on 09/28/21 revealed a mass in the pancreatic head in contact with the SMV (approximately 90 degrees) and suspected lymph node metastasis close to the SMA.\n2. The findings did not mention any distant metastases, so option A is unlikely to be correct.\n3. The mass in the pancreatic head was in contact with the SMV, not the SMA, so option B is incorrect.\n4. The suspicious regional lymph nodes were particularly noted in the interaortocaval space, not the anterocaval region, so option C is incorrect.\n5. The liver showed signs of fatty infiltration, which is consistent with option D.\n6. The spleen's vein was not involved, according to the findings, so option E is incorrect.\n\nBased on the analysis, the correct answer is:\n\nD"
    },
    {
      "question_id": "patient_04_q4",
      "generated_text": "To answer this question, let's follow the steps:\n\n1. Review the text: The text provides information about Mrs. Anderson's treatment for pancreatic cancer, including her diagnosis, CT scans, ERCP, and biopsy results.\n2. Identify the relevant information: The text mentions a Gastrointestinal Tumor Board meeting on September 30, 2021, where the board discussed Mrs. Anderson's treatment plan.\n3. Analyze the options: The options provided are different treatment recommendations for Mrs. Anderson's pancreatic cancer.\n4. Match the information to the options: According to the text, the Gastrointestinal Tumor Board recommended \"neoadjuvant chemotherapy with FOLFIRINOX\" and to \"review after 4 cycles.\"\n\nBased on the information provided, the correct answer is:\n\n**C**"
    },
    {
      "question_id": "patient_04_q5",
      "generated_text": "To answer this question, I will follow these steps:\n\n1. Identify the patient: Jill Anderson, born 1975-07-06 00:00:00\n2. Identify the relevant procedure: Exploratory laparotomy\n3. Identify the relevant finding: Histopathological finding related to the gallbladder\n4. Find the relevant text snippet in the provided texts that describes the exploratory laparotomy and histopathological findings\n5. Analyze the text snippet to determine the correct answer\n\nThe relevant text snippet is from text_7:\n\n\"Surgery Report:\n\nDiagnosis: Locally advanced pancreatic head cancer post 4 cycles of\nFOLFIRINOX.\n\nProcedure:\n\nExploratory laparotomy, adhesion removal, pancreatic head and vascular\nvisualization, biopsy of distal mesenteric root area, surgery halted due\nto positive frozen section results, gallbladder removal, catheter placement,\nand 2 drains.\n\nReport:\n\nMrs. Anderson has a pancreatic head cancer and had received 4 cycles of\nFOLFIRINOX neoadjuvant therapy. The surgery involved a detailed\nabdominal exploration which did not reveal any liver metastases or\nperitoneal cancer spread. However, a hard nodule was found away from the\nhead of the pancreas in the peripheral mesenteric root, from which a\nbiopsy was taken. Results showed adenocarcinoma infiltrates, leading to\nthe surgery's termination. An additional gallbladder removal was performed\ndue to its congested appearance.\"\n\nBased on this text snippet, the histopathological finding related to the gallbladder is that it had a congested appearance, which led to its removal.\n\nTherefore, the correct answer is:\n\nC"
    },
    {
      "question_id": "patient_04_q6",
      "generated_text": "To determine the correct answer, let's analyze the information provided in the text about Mrs. Anderson's CT scan from September 28, 2021.\n\nThe text mentions that the CT scan revealed a mass in the pancreatic head with contact to the SMV (superior mesenteric vein) (approximately 90 degrees) and suspected lymph node metastasis near the SMA (superior mesenteric artery). There was also significant dilation of the intra- or extrahepatic bile ducts and the pancreatic duct.\n\nGiven this information, we can evaluate the options:\n\nA. A hypodense mass measuring 34 x 28 mm: This option is mentioned in the text, so it is a possible correct answer.\n\nB. It had direct contact with the liver: The text does not mention any contact between the mass and the liver.\n\nC. It was >180\u00b0 around the superior mesenteric artery: The text actually states that the mass had contact with the SMA (superior mesenteric artery) (approximately 90 degrees), not >180\u00b0.\n\nD. No dilation of the pancreatic duct was observed: The text actually states that there was dilation of the pancreatic duct.\n\nE. None of the above: Since option A is a correct statement according to the text, this option is incorrect.\n\nConsidering the information provided, the correct answer is:\n\nA"
    },
    {
      "question_id": "patient_04_q7",
      "generated_text": "To determine the correct sequence of radiologic examinations, let's break down the information provided in the text about Mrs. Anderson's patient ID: 04.\n\nThe text mentions the following radiologic examinations for Mrs. Anderson:\n\n1. Shoulder X-ray (07/08/2014)\n2. Right ankle X-ray (02/01/2015)\n3. Chest X-ray (07/20/2023)\n4. Chest/abdomen/pelvis CT (09/28/2021, 09/28/2021)\n5. Ultrasound (09/29/2021)\n6. Abdominal MRI (09/28/2021)\n7. CT staging (09/28/2021, 12/02/2022)\n8. CT Chest/Abdomen/Pelvis with contrast (04/02/2023)\n\nGiven this information, the correct sequence of radiologic examinations in chronological order is:\n\nFoot X-ray > Shoulder X-ray > Right ankle X-ray > Chest/abdomen/pelvis CT > Ultrasound > Abdominal MRI > CT staging > CT staging > CT Chest/Abdomen/Pelvis with contrast\n\nThe correct answer is **C**."
    },
    {
      "question_id": "patient_04_q8",
      "generated_text": "To determine the correct answer, let's analyze the information provided in the text:\n\n1. The GI Tumor Board Review on January 9th, 2022, discussed Mrs. Anderson's case.\n2. The review mentioned a CT scan, but it did not specify the date of the CT scan.\n3. The review mentioned that the primary tumor had reduced in size with decreased contact with the aorta, but new tumor extension towards the celiac trunk was noted.\n4. It also mentioned that no distant metastases were found.\n\nBased on this information, we can conclude that the CT scan did not show signs of liver metastases (A) or distant metastases (D). It also did not indicate remission of her tumor (B), as the tumor had reduced in size but not completely disappeared. Therefore, the correct answer is:\n\nC. The CT scan showed progression of her tumor.\n\nHowever, this answer choice is not entirely accurate. The correct interpretation is that the tumor had reduced in size but had a new extension, which could be considered a progression of the tumor in some contexts. But based on the options provided, C is the closest correct answer.\n\nIf I had to choose, I would choose C, but I want to clarify that it's not a perfect answer based on the information provided.\n\n**C**"
    },
    {
      "question_id": "patient_04_q9",
      "generated_text": "To answer this question, I will follow these steps:\n\n1. Identify the relevant text: The relevant text is in text_7.\n2. Find the information about Mrs. Anderson's tumor marker Ca19-9 levels in September 2021: In text_7, the information is in the sentence: \"Tumor marker Ca19-9 levels: 525 U/mL (previously 575 U/mL in September and 380 U/mL in November).\"\n\n3. From the text, I can see that Mrs. Anderson's tumor marker Ca19-9 levels in September 2021 were 575 U/mL, but also previously 575 U/mL, and 380 U/mL in November. However, I am looking for the September 2021 value. Since the text says \"previously 575 U/mL in September\", it implies that the value in September 2021 was 575 U/mL.\n\n\n**B.**"
    },
    {
      "question_id": "patient_04_q10",
      "generated_text": "Let's break down the information provided about Mrs. Anderson's chemotherapy:\n\n1. Mrs. Anderson was diagnosed with pancreatic cancer and underwent a pancreatic head resection.\n2. She received neoadjuvant chemotherapy with FOLFIRINOX from 10/21 to 12/21 (4 cycles).\n3. After surgery, she received 4 cycles of gemcitabine/5-FU (adjuvant chemotherapy) from 01/23 to 04/23.\n4. Later, she received 2 cycles of gemcitabine/nab-paclitaxel from 06/23 to 07/23, and then another cycle was added in 07/23, making it a total of 3 cycles.\n5. In 07/22, she started gemcitabine/nab-paclitaxel and PRRT with lutetium-177 FAP.\n\nConsidering the information provided, the correct statement is:\n\n**C**\n\nGemcitabine/nab-paclitaxel was started in 07/22 after surgery, but it was not started in 02/22."
    },
    {
      "question_id": "patient_04_q11",
      "generated_text": "To answer this question, let's analyze the information provided in the text related to Mrs. Anderson's CT scans.\n\nIn the text, it is mentioned that a CT scan was performed on 04/02/2023, and the findings were as follows:\n\n\"Chest: Normal lung aeration, fully expanded to the chest wall. No pneumothorax detected. Known metastatic lung nodules show increased size in this study. For instance, the nodule in the apical segment of the right lower lobe now measures 17 x 15 mm, previously around 8 x 10 mm. Similarly, a solid nodule in the right posterior basal segment of the lower lobe is now 12 mm (previously 8 mm) with adjacent atelectasis. No signs of pneumonia. No pleural effusions. Homogeneous thyroid tissue with a nodule on the left side. Solitary lymph nodes seen in the left axillary region and previously smaller (now 9 mm, was 4mm) but with a retained fatty hilum, suggesting an inflammatory origin. No other evidence of abnormally enlarged or conspicuously shaped mediastinal or hilar lymph nodes. A port catheter is inserted from the right, with its tip in the superior vena cava; no signs of port tip thrombosis. Mild coronary artery sclerosis.\"\n\nBased on this information, we can see that the known metastatic lung nodules increased in size.\n\n**C**"
    },
    {
      "question_id": "patient_04_q12",
      "generated_text": "To answer this question, let's analyze the given information step by step:\n\n1. The patient, Mrs. Anderson, was initially diagnosed with pancreatic cancer and underwent neoadjuvant FOLFIRINOX therapy.\n2. The treatment plan was changed to gemcitabine/nab-paclitaxel after the initial therapy.\n3. There is no mention of FOLFIRINOX being unavailable or the patient showing allergic reactions to it.\n4. The mention of palliative therapy is not relevant to the change in treatment plan.\n5. The reason for the change in therapy is not explicitly stated, but the progression of the disease is mentioned in the context of the treatment plan, suggesting that the disease progressed despite neoadjuvant FOLFIRINOX therapy.\n\nConsidering the information provided, the most logical reason for the shift from neoadjuvant FOLFIRINOX therapy to gemcitabine/nab-paclitaxel is disease progression despite neoadjuvant FOLFIRINOX therapy.\n\nD."
    },
    {
      "question_id": "patient_04_q13",
      "generated_text": "To answer this question, let's analyze the CT scan findings for Mrs. Anderson dated 12/02/2022.\n\nAccording to the provided text, the CT scan findings are:\n\n- A mass in the pancreatic head with contact to the SMV (approximately 90 degrees) and suspected lymph node metastasis near the SMA.\n- Significant dilation of the intra- or extrahepatic bile ducts and the pancreatic duct.\n- Suspicious regional lymph nodes, especially in the interaortocaval region.\n- No distant metastases.\n- A small low-density area in the spleen, possibly a splenic cyst.\n- Two distinct low-density areas in the right kidney's tissue, likely cysts.\n- Pancreatic tumor decreasing in size.\n- Local lymph nodes and nodules in the mesentery, with sizes up to about 9mm; some are near the intestines, also decreasing in size.\n- Outpouchings (diverticula) in the left-sided colon.\n- Hardening of the abdominal vessels.\n- An elongation of the right iliac artery is noted.\n- There are degenerative changes, including a forward slip of the fifth lumbar vertebra over the first sacral vertebra (grade 1-2 spondylolisthesis).\n- An indentation at the top of the tenth thoracic vertebra.\n\nBased on these findings, we can determine that:\n\nThe correct answer is **B**. Suspicious pulmonary nodules are not mentioned in the findings of the CT scan dated 12/02/2022."
    },
    {
      "question_id": "patient_04_q14",
      "generated_text": "To determine the correct diagnosis, let's break down the information provided:\n\n1. The patient, Mrs. Anderson, was in inpatient treatment from 07/20/2023 to 09/12/2023.\n2. The diagnosis during this period is specified as \"Seropneumothorax secondary to punction of a malignant pleural effusion with progressive pulmonary metastasis of a pancreatic head carcinoma.\"\n\nGiven this information, the correct answer is:\n\nC"
    },
    {
      "question_id": "patient_04_q15",
      "generated_text": "To answer this question, let's break it down step by step:\n\n1. The patient, Mrs. Jill Anderson, has a diagnosis of pancreatic cancer.\n2. She is experiencing mental health concerns, which are likely related to her cancer diagnosis and treatment.\n3. We need to find the medication that was prescribed for her mental health concerns.\n\nLooking through the text, we can see that in text_8, there is a section on \"Psycho-oncology consult from 9/10/2023\" which mentions that the patient is \"notably stressed due to her physical limitations in the current scenario, leading to supply concerns. She is under added strain because her insurance recently denied a care level. She dwells on this and suffers from sleep disturbances. She also experiences pain but is hesitant about 'imposing' and requesting painkillers.\"\n\nLater in the same text, it is mentioned that \"A diagnostic and supportive discussion was held. We recommended mirtazapine 7.5 mg at night, increasing to 15 mg after a week if tolerated well. She was also encouraged to take pain medication with Tylenol proactively or at fixed intervals if needed.\"\n\nTherefore, the medication prescribed for Mrs. Anderson's mental health concerns is Mirtazapine.\n\n**C**"
    },
    {
      "question_id": "patient_04_q16",
      "generated_text": "To answer this question, let's analyze the information provided in the text regarding Mrs. Anderson's pleural effusion status as of her discharge in September 2023.\n\nFrom the text, we know that Mrs. Anderson was admitted to the hospital due to worsening shortness of breath and was suspected to have a pleural effusion. A chest tube was inserted, and the fluid was drained. The pathology report from the fluid sample showed atypical cells consistent with pancreatic cancer.\n\nHowever, the text does not provide specific information about the pleural effusion status as of her discharge in September 2023. It only mentions that the patient was discharged on 9/28/2023 in stable condition and without symptoms.\n\nGiven this information, we cannot determine the exact status of Mrs. Anderson's pleural effusion as of her discharge. However, we can infer that the pleural effusion was likely managed and resolved, as she was discharged in stable condition.\n\nSo, based on this analysis, my best guess is:\n\nC. Drastically improved with no evidence of fluid"
    },
    {
      "question_id": "patient_04_q17",
      "generated_text": "To determine which of the findings was NOT present in Mrs. Anderson's liquid sample, let's examine the pathology report from 07/26/2023.\n\nThe report mentions the following findings in the liquid sample:\n\n- Red blood cells\n- Atypical cells in clusters\n- Many granulocytes\n- Evidence of a malignant cell population suggestive of adenocarcinoma cells\n- Active mesothelium\n\nThe report does not mention any evidence of a fungal infection.\n\nSo, the correct answer is: \nC"
    },
    {
      "question_id": "patient_04_q18",
      "generated_text": "Based on the sequence of interventions and radiologic findings, the events occurred in the following order:\n\n1. A pleural effusion was initially drained.\n2. The pleural effusion was followed by a seropneumothorax, which was not immediately drained.\n3. A chest tube was inserted on 07/24/2023, which immediately drained 500 mL of fluid.\n4. After the chest tube placement, Mrs. Anderson's oxygen saturation improved.\n5. A pathology report from the pleural puncture sample diagnosed the fluid as originating from a pancreatic-biliary cancer.\n\nConsidering the sequence of events, the correct answer is:\n\nD. The pleural effusion that was initially drained led to an improvement in oxygen saturation, but was followed by the development of a seropneumothorax, necessitating a chest tube placement."
    },
    {
      "question_id": "patient_04_q19",
      "generated_text": "To determine which medication was present during Mrs. Anderson's initial therapy but not at the time of the last discharge, we need to look at the medication lists provided for each of her hospital stays.\n\nFrom the provided texts, we can see that Mrs. Anderson was admitted multiple times for her pancreatic cancer treatment. The medication lists for each admission are as follows:\n\n- Initial therapy (09/21):\n  - Lovenox (40mg s.c. daily)\n  - Paracetamol (as required)\n  - Mirtazapine (7.5 mg at night)\n  - Pancreatic enzymes (25,000 IU main meals, 10,000 IU snacks)\n\n- Later therapy (07/22):\n  - Lovenox (0.2 mL subcutaneously; once daily in the evening on non-dialysis days)\n  - Paracetamol (as required)\n  - Mirtazapine (7.5 mg at night)\n  - Pancreatic enzymes (25,000 IU main meals, 10,000 IU snacks)\n\n- Later therapy (09/12/2023):\n  - Mirtazapine (7.5 mg at night)\n  - Paracetamol (as required)\n  - Pancreatic enzymes (25,000 IU main meals, 10,000 IU snacks)\n\nBased on the medication lists provided, we can see that Lovenox was present during Mrs. Anderson's initial therapy but was not present at the time of her last discharge.\n\n**A**"
    },
    {
      "question_id": "patient_05_q0",
      "generated_text": "Let's analyze the information step by step:\n\n1. The patient, Mr. John Miller, was born on July 4, 1961.\n2. He was admitted due to a sudden onset of symptoms.\n3. The symptoms that led to his admission were related to his brain.\n4. The symptoms included speech difficulties and confusion.\n\nConsidering these points, the most likely initial presentation that led Mr. John Miller to be admitted was related to his brain and involved speech difficulties.\n\n**C**"
    },
    {
      "question_id": "patient_05_q1",
      "generated_text": "To determine when Mr. Miller's glioblastoma recurrence was resected, we need to look for the date of the second surgery in the provided texts.\n\nStep 1: The first surgery for glioblastoma was performed on 08/11/2019 (text_0).\n\nStep 2: We need to find the date of the second surgery, which is the recurrence of the glioblastoma.\n\nStep 3: In text_1, it is mentioned that the patient had a suspected recurrence in 07/2019 and underwent surgery on 08/11/2019. However, this is not the second surgery for the recurrence.\n\nStep 4: In text_2, it is mentioned that the patient had a recent PET-MRI on 01/2020, which indicated potential recurrent areas.\n\nStep 5: In text_3, it is mentioned that the patient had a second surgery on 04/12/2020, but this is not the correct answer as it is not a recurrence of the glioblastoma.\n\nStep 6: In text_4, it is mentioned that the patient had a suspected recurrence with new FLAIR-positive tumor manifestation insular on the right side in 02/2021.\n\nStep 7: In text_5, it is mentioned that the patient underwent a stereotactic biopsy with histopathology with evidence of glioblastoma in 02/2021, but this is not the date of the second surgery.\n\nStep 8: In text_5, it is also mentioned that the tumor board recommended new radiochemotherapy up to a total dose of 60 Gy \u00e0 2 Gy single dose, but this is not the date of the second surgery.\n\nStep 9: In text_6, it is mentioned that the patient underwent a repeat stereotactic RTx in the area of the basal ganglia and the resection cavity right frontal on the Gamma Knife with 46 Gy \u00e0 2 Gy; 3 doses of Bevacizumab 7.5 mg/kg i.v., but this is not the date of the second surgery.\n\nStep 10: In text_1, it is mentioned that the patient had a recurrent resection on 10/12/2019.\n\nTherefore, the correct answer is D."
    },
    {
      "question_id": "patient_05_q2",
      "generated_text": "To answer this question, I will follow these steps:\n\n1. Identify the key information in the text about Mr. Miller's condition.\n2. Look for the specific information related to molecular pathology findings.\n3. Match the information with the options provided.\n\nFrom the text, I can see that the key information related to molecular pathology findings for Mr. Miller's glioblastoma is mentioned in the section starting with \"Molecular Pathology: No p.R132H mutation in IDH. No combined 1p/19q loss. Suspected CDKN2A/B deletion.\"\n\nBased on this information, the correct answer is:\n\nC"
    },
    {
      "question_id": "patient_05_q3",
      "generated_text": "To determine the correct answer, let's break down the information provided about Mr. Miller's CT scan on 09/28/21.\n\nThe question asks about the duration of the CT scan procedure. However, the provided text does not explicitly mention the duration of the CT scan procedure. It only mentions the technique used, which includes the administration of contrast material and the performance of the scan during arterial, parenchymal, and venous phases, as well as the use of oral contrast.\n\nSince the duration of the CT scan is not explicitly mentioned in the provided text, I will make an educated guess based on the information typically associated with CT scans. A standard CT scan can take anywhere from a few minutes to several hours, depending on the type of scan and the body part being scanned. However, the provided text does not provide enough information to accurately determine the duration of the CT scan.\n\nGiven the lack of specific information, I will randomly select an option. \n\nC"
    },
    {
      "question_id": "patient_05_q4",
      "generated_text": "To determine how Mr. Miller's Karnofsky Performance Score (KPS) changes over the course of therapy, we need to find the initial and final KPS values from the provided text.\n\nThe initial KPS is mentioned in the text as 70% in several instances, including in the following:\n\n- \"Physical examination findings at discharge: Patient awake, fully oriented, cooperative. Speech clear and fluent. Cranial nerve status without pathological findings. Hemiparesis left-sided strength grade 4/5, right-sided no sensorimotor deficit. Stance and gait unsteady. Non-fluent aphasia. Wound dry, without irritation. Karnofsky 70%.\"\n- \"Clinical examination findings at discharge: Patient awake, fully oriented, cooperative. Speech clear and fluent. Cranial nerve status without pathological findings. Hemiparesis left-sided strength grade 4/5, right-sided no sensorimotor deficit. Stance and gait unsteady. Non-fluent aphasia. Wound dry, without irritation. Karnofsky 70%.\"\n\nThe final KPS is mentioned as 80% in the following:\n\n- \"Patient awake, fully oriented, cooperative. Non-fluent aphasia. Speech clear and fluent. Latent left hemisymptomatic with strength grades 4+/5, stance and gait unsteady. Cranial nerve status regular. Scar conditions non-irritant except for frontal superficial erosion at frontal wound pole of pterional approach. Karnofsky 80%.\"\n\nGiven these values, Mr. Miller's KPS increases from 70% to 80%.\n\nThe correct answer is: D."
    },
    {
      "question_id": "patient_05_q5",
      "generated_text": "To determine the correct answer, I will follow these steps:\n\n1. Review the provided text to find the relevant information about the Interdisciplinary Neuro-oncological Tumor Board meeting on 04/20/2020.\n2. Identify the recommendation given by the board during this meeting.\n\nAccording to the text, the Interdisciplinary Neuro-oncological Tumor Board on 04/20/2020 recommended \"Molecular tumor board review. Offer reinitiation of Temozolomide chemotherapy.\"\n\nTherefore, the correct answer is:\n\nD"
    },
    {
      "question_id": "patient_05_q6",
      "generated_text": "To determine which medication was increased in dosage during Mr. Miller's therapy, let's analyze the provided information.\n\nFrom the text, we have information about Mr. Miller's medical history and medication list, but we need to find a specific mention of dosage changes.\n\nIn text_3, we see that Mr. Miller has a medical history of Hypertension and Type II Diabetes Mellitus, and he is taking various medications.\n\nUpon reviewing the text, we can see that in text_3, Mr. Miller's medications are listed, but there is no information about dosage changes.\n\nHowever, in text_4, it mentions that the medication with lorazepam should be phased out over time, but there is no information about increasing the dosage of any medication.\n\nIn text_5, it mentions that Mr. Miller received physiotherapeutic exercise and psychotherapy during the entire therapy, and his motor skills improved significantly. However, there is no information about dosage changes for his medications.\n\nIn text_6, it mentions that Mr. Miller experienced some cognitive challenges and fatigue, but there is no information about dosage changes for his medications.\n\nSince there is no clear information about dosage changes for any of the medications in the provided texts, I will make an educated guess based on the information available.\n\nGiven the context, I'm not sure which medication was increased in dosage during Mr. Miller's therapy. However, I will make a guess based on the information provided.\n\nD. Januvia"
    },
    {
      "question_id": "patient_05_q7",
      "generated_text": "To determine the correct answer, let's break down the information provided in the text related to Mr. Miller's radiotherapy.\n\n1. The text mentions that Mr. Miller underwent radiochemotherapy in 03-04/2021.\n2. It states that the radiotherapy was administered to the former recurrence tumor region in the frontal/insular right after CT- and MRI-guided radiation planning with 6 MV-photons in helical tomotherapy technique.\n3. Additionally, it mentions that local dose saturation of the macroscopic tumor remnant was performed using the GammaKnife with a dose of 6 Gy in 2 Gy single dose to the 68% isodose up to a total cumulative dose of 66 Gy.\n\nFrom this information, we can infer that Mr. Miller received two types of radiotherapy:\n\n- **Helical tomotherapy** (option D) was used for the initial radiotherapy session.\n- **GammaKnife** (option C) was used for the local dose saturation of the macroscopic tumor remnant.\n\nSince the question asks for the method employed for Mr. Miller's radiotherapy, and both options D and C are mentioned as separate methods, the correct answer is:\n\n**E. Both a) and d)**"
    },
    {
      "question_id": "patient_05_q8",
      "generated_text": "To determine the correct answer, I will follow the steps below:\n\n1. Review the MRI report dated 02/02/2021 for Mr. Miller.\n2. Identify the relevant information regarding the options provided.\n\nAccording to the MRI report dated 02/02/2021:\n\n- The report states: \"The midline shift is approximately 9mm to the left, which remains unchanged.\"\n- It also mentions: \"Post-operative swelling and fluid accumulation are noted at the surgical entry point.\"\n- The orbital contents are symmetrical.\n- Residual blood products are noted within the resection cavity.\n- The paranasal sinuses and mastoid air cells are aerated appropriately.\n\nBased on the information provided, the correct answer is:\n\nD. Residual blood products are noted within the resection cavity."
    },
    {
      "question_id": "patient_05_q9",
      "generated_text": "To determine the correct answer, let's examine the medication changes for Mr. John Miller step by step:\n\n1. Initially, Mr. Miller was prescribed Levetiracetam at 1000mg once daily in the morning, but this dosage is not mentioned in the discharge medication list. However, Lacosamide 100 mg is mentioned in the discharge medication list, but its initial dosage is not provided in the earlier prescriptions. It is possible that Lacosamide was prescribed at discharge, but we cannot confirm the change in dosage for Levetiracetam.\n\n2. Lisinopril was initially prescribed at 10mg once daily in the morning, but this dosage is not mentioned in the discharge medication list. However, Lacosamide 100 mg is mentioned in the discharge medication list, and it is not mentioned in the earlier prescriptions. Therefore, it appears that Lisinopril was replaced by Lacosamide.\n\n3. Sertraline was initially prescribed at 50mg twice daily, but this dosage is not mentioned in the discharge medication list. However, Sertraline 50mg by regimen is mentioned in the discharge medication list. It seems that the dosage was maintained.\n\n4. Januvia was initially given at 50 mg twice daily, and this dosage is not mentioned in the discharge medication list. However, Levothyroxine sodium 50 \u03bcg is mentioned in the discharge medication list, and it is not mentioned in the earlier prescriptions. Therefore, it appears that Januvia was discontinued and replaced by Levothyroxine.\n\n5. Ezetimibe and Bisoprolol were initially given at bedtime, but their combination is not mentioned in the discharge medication list. However, Acetaminophen 500 mg is mentioned in the discharge medication list, and it is prescribed to be taken four times daily. It seems that Ezetimibe and Bisoprolol were not combined into Acetaminophen.\n\nConsidering these changes, the correct answer is B."
    },
    {
      "question_id": "patient_05_q10",
      "generated_text": "To determine the correct answer, let's analyze the provided text.\n\n1. The first mention of Mr. John Miller's glioblastoma diagnosis and treatment is in 07/2019, where a glioblastoma was resected at the facility.\n2. In 08-09/2019, he underwent adjuvant radiochemotherapy and Temodal treatment at the local clinical center.\n3. In 10/01/2019, a cMRI with suspected recurrence was conducted.\n4. In 10/12/2019, a recurrent resection was performed at the facility.\n5. In 04/2020, a revision surgery was performed due to a wound healing disorder.\n6. In 06-07/2020, wound revisions and flap plasty were performed for atrophic wound healing disorder.\n7. In 02/2021, a stereotactic biopsy with evidence of glioblastoma was conducted, and radiochemotherapy was recommended.\n\nFrom this information, we can see that there were at least three glioblastoma resections performed on Mr. John Miller by the reporting facility prior to 2021: one in 07/2019, one in 10/12/2019, and one in 04/2020 is not a resection but a revision surgery due to wound healing disorder, and 06-07/2020 is also not a resection but a wound revision and flap plasty. Therefore, there are only two distinct glioblastoma resections.\n\n**B**"
    },
    {
      "question_id": "patient_05_q11",
      "generated_text": "To answer this question, let's follow the steps:\n\n1. The question is asking about the area that showed a notable reduction in the barrier disturbance in Mr. Miller's cMRI scan from 06/02/2021.\n2. We need to find the relevant information in the provided text about Mr. Miller's cMRI scan from 06/02/2021.\n3. The relevant text is from text_6: **Summary:**\n   On 07/03/2023, we conducted an initial telephone follow-up with the\n   patient, Mr. Miller, for a radio-oncology consultation. Presently, Mr.\n   Miller is undergoing rehabilitation, from which he feels he is deriving\n   substantial benefits. His recent radiotherapy was well-received without\n   any complications. Since the onset of his symptoms, there have been no\n   new developments. Symptoms related to intracranial pressure or new\n   neurological deficits were denied. Fortunately, while on anticonvulsant\n   therapy with Lacosamide, Mr. Miller experienced no epileptic seizures.\n   His skin condition is normal. However, Mr. Miller did mention some\n   cognitive challenges that minimally impact his daily activities,\n   alongside feelings of fatigue and grade I CTCAE symptoms. The cMRI scan\n   from 06/02/2021 revealed a notable reduction in the barrier disturbance\n   of the right-sided basal ganglia. This was accompanied by small, mildly\n   hyperperfused residual findings near the third ventricle. Moreover, the\n   pinpoint contrast enhancement in the left parietal lobe appeared\n   unchanged, suggesting it is a scarring reaction.\n\n4. According to the text, the area that showed a notable reduction in the barrier disturbance in Mr. Miller's cMRI scan from 06/02/2021 is the right-sided basal ganglia.\n\n**C**"
    },
    {
      "question_id": "patient_05_q12",
      "generated_text": "To answer this question, I'll go through the provided text and look for any relevant information about Mr. John Miller's scheduled imaging modality on 06/02/2021.\n\nFirst, I'll search for the date 06/02/2021 in the text and look for any mentions of imaging modalities.\n\nAfter searching the text, I found the following relevant information:\n\n\"...An imaging exam (brain MRI) is scheduled for 06/02/2021 at 10:30 AM...\"\n\nBased on this information, I can conclude that the imaging modality scheduled for Mr. John Miller on 06/02/2021 was an MRI.\n\n**C**"
    },
    {
      "question_id": "patient_05_q13",
      "generated_text": "To determine which medication was not mentioned in Mr. Miller's report on admission in 2019, let's analyze the medications listed in the report:\n\n- Lacosamide 100 mg/1 pc is mentioned as part of Mr. Miller's medication regimen.\n- Lorazepam 0.5 mg/1 pc is also mentioned in the report.\n- Levothyroxine sodium 50 \u03bcg/1 pc is mentioned as part of Mr. Miller's medication regimen.\n- Acetaminophen 500 mg is mentioned as a medication prescribed for pain or fever.\n- Sertraline 50 mg is not mentioned in the report on admission in 2019.\n\nTherefore, the correct answer is:\n\nE"
    },
    {
      "question_id": "patient_05_q14",
      "generated_text": "To answer this question, I will go through the information provided in the text about Mr. Miller's molecular pathological findings.\n\nThe text states that Mr. Miller's glioblastoma is IDH wild type, which suggests that the IDH status is known, so option B is incorrect.\n\nThe text also mentions that the ATRX status is preserved, which is a molecular pathological finding, so option A is incorrect.\n\nThe text mentions that the CDKN2A/B is deleted, which is another molecular pathological finding, so option D is incorrect.\n\nThe text also mentions that the MGMT promoter is methylated, which is a molecular pathological finding, so option E is incorrect.\n\nThe text states that the p53 status is \"technically not evaluable (immunohistochemical)\", which means that the p53 status could not be determined using immunohistochemistry.\n\nTherefore, the correct answer is:\n\nC"
    },
    {
      "question_id": "patient_05_q15",
      "generated_text": "To answer this question, I need to find the text that contains the information about Mr. Miller's symptoms.\n\nThe relevant text is from text_0, where it says: \n-07/2019: Onset of speech disturbances and confusion.\n\nSo, Mr. Miller first experienced symptoms such as speech disturbances and confusion in July 2019.\n\nThe correct answer is: C"
    },
    {
      "question_id": "patient_05_q16",
      "generated_text": "To answer this question, I will follow the steps:\n\n1. Identify the patient ID: ID patient_05\n2. Identify the patient's name and birthday: John Miller, 1961-07-04 00:00:00\n3. Identify the diagnosis: Cerebral glioblastoma\n4. Search through the reports for any mention of the patient's height\n5. Find the report that mentions the height: In the report dated 12/01/2019, it is mentioned that Mr. Miller's height is 169 cm.\n\nThe correct answer is: A"
    },
    {
      "question_id": "patient_05_q17",
      "generated_text": "To answer this question, I will analyze the pathology report from 07/26/2023 step by step.\n\nThe report mentions the following findings:\n\n- IDH status: no p.R132H mutation\n- ATRX: preservation of nuclear expression\n- p53: technically not evaluable\n- 1p/19q status: no combined loss\n- CDKN2A/B: Deleted\n- MGMT promoter: Methylated\n\nGiven this information, I will identify the correct answer:\n\nCDKN2A/B: Deleted is present in the report. \nIDH mutation (R132H) is not mentioned as present. \np53: technically not evaluable is present in the report. \nMGMT promoter: Methylated is present in the report. \n\nSo, the correct answer is the one that does not match the findings in the report.\n\nA. IDH mutation (R132H) is the correct answer."
    },
    {
      "question_id": "patient_05_q18",
      "generated_text": "To determine which development in Mr. Miller's treatment occurred on 02/2021, let's review the timeline of events provided in the text.\n\nFirst, we know that Mr. Miller had a glioblastoma resection on 08/11/2019, and subsequent surgeries and treatments followed. However, the timeline for 02/2021 is specifically mentioned in text_5.\n\nAccording to text_5, the relevant information for 02/2021 is: \"02/2021: Suspected recurrence with new FLAIR-positive tumor manifestation insular on the right side. Stereotactic biopsy with evidence of glioblastoma.\"\n\nGiven this information, we can conclude that the development in Mr. Miller's treatment that occurred on 02/2021 was the new FLAIR-positive tumor manifestation insular on the right side.\n\n**B**"
    },
    {
      "question_id": "patient_05_q19",
      "generated_text": "To determine the correct order of imaging tests performed for John Miller, we need to analyze the given text and identify the sequence of imaging tests mentioned.\n\nThe text mentions the following imaging tests for John Miller:\n\n1. PET-MRI (07/2019)\n2. cMRI (08/01/2019)\n3. cMRI (08/11/2019)\n4. cMRI (10/01/2019)\n5. iMRI (10/12/2019)\n6. cMRI (11/02/2019)\n7. PET-MRI (01/2020)\n8. cMRI (02/02/2021)\n9. cMRI (09/15/2020)\n10. iMRI (09/18/2020)\n11. PET-MRI (04/11/2021)\n\nBased on the given sequence, the correct order of imaging tests performed for John Miller is:\n\ncMRI < PET-MRI < cMRI < cMRI < iMRI < cMRI < cMRI < PET-MRI < PET-MRI < cMRI < cMRI < cMRI < cMRI\n\n**D**"
    }
  ]
}